2,007 results on '"M, Thomson"'
Search Results
2. Successes and challenges of partnership working to tackle health inequalities using collaborative approaches to community-based research: mixed methods analysis of focus group evidence
- Author
-
L. J. M. Thomson, H. Waterson, and H. J. Chatterjee
- Subjects
Communities ,Community assets ,Community-based participatory research ,Focus groups ,Health inequalities ,Integrated care ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background The concept of collaborative approaches involves community residents in joint decision-making processes to maintain or enhance their material and social conditions. During COVID-19, public services saw the benefits of actively collaborating with communities and involving residents in decision-making processes. As communities have resources and assets, they are well-placed to contribute to developing local health and wellbeing initiatives. An interdisciplinary and nationally funded three-phase research programme, “Mobilising community assets to tackle health inequalities”, was established with the objective of utilising local, cultural, and natural assets to support health and wellbeing. The current study aimed to synthesise evidence collected by research teams awarded funding in phase one of the programme, comprising academic and non-academic, health and social care, voluntary and community partners. Methods Ten online focus groups were conducted with research teams from across the UK exploring the successes and challenges of partnership working to tackle health inequalities using collaborative approaches to community-based research. Eight focus group questions were split between partnership working and health inequalities. Results Thematic and content analysis produced 185 subthemes from which 12 themes were identified. Major themes representing an above average number of coded responses were research evidence; funding; relationships with partners; health inequalities and deprivation; community involvement; and health service and integrated care systems. Minor themes were link workers and social prescribing; training and support; place-based factors; longevity of programmes; setting up and scaling up programmes; and mental health. Conclusions Successes included employing practice-based and arts-based methods, being part of a research project for those not normally involved in research, sharing funding democratically, building on established relationships, and the vital role that local assets play in involving communities. Challenges involved a lack of sustainable financial support, the short-term nature of funding, inconsistencies in reaching the poorest people, obtaining the right sort of research evidence, making sufficient research progress, building relationships with already over-burdened health care staff, and redressing the balance of power in favour of communities. Despite the challenges, participants were mainly optimistic that collective approaches and meaningful co-production would create opportunities for future research partnerships with communities.
- Published
- 2024
- Full Text
- View/download PDF
3. Community-based reconstruction and simulation of a full-scale model of the rat hippocampus CA1 region.
- Author
-
Armando Romani, Alberto Antonietti, Davide Bella, Julian Budd, Elisabetta Giacalone, Kerem Kurban, Sára Sáray, Marwan Abdellah, Alexis Arnaudon, Elvis Boci, Cristina Colangelo, Jean-Denis Courcol, Thomas Delemontex, András Ecker, Joanne Falck, Cyrille Favreau, Michael Gevaert, Juan B Hernando, Joni Herttuainen, Genrich Ivaska, Lida Kanari, Anna-Kristin Kaufmann, James Gonzalo King, Pramod Kumbhar, Sigrun Lange, Huanxiang Lu, Carmen Alina Lupascu, Rosanna Migliore, Fabien Petitjean, Judit Planas, Pranav Rai, Srikanth Ramaswamy, Michael W Reimann, Juan Luis Riquelme, Nadir Román Guerrero, Ying Shi, Vishal Sood, Mohameth François Sy, Werner Van Geit, Liesbeth Vanherpe, Tamás F Freund, Audrey Mercer, Eilif Muller, Felix Schürmann, Alex M Thomson, Michele Migliore, Szabolcs Káli, and Henry Markram
- Subjects
Biology (General) ,QH301-705.5 - Abstract
The CA1 region of the hippocampus is one of the most studied regions of the rodent brain, thought to play an important role in cognitive functions such as memory and spatial navigation. Despite a wealth of experimental data on its structure and function, it has been challenging to integrate information obtained from diverse experimental approaches. To address this challenge, we present a community-based, full-scale in silico model of the rat CA1 that integrates a broad range of experimental data, from synapse to network, including the reconstruction of its principal afferents, the Schaffer collaterals, and a model of the effects that acetylcholine has on the system. We tested and validated each model component and the final network model, and made input data, assumptions, and strategies explicit and transparent. The unique flexibility of the model allows scientists to potentially address a range of scientific questions. In this article, we describe the methods used to set up simulations to reproduce in vitro and in vivo experiments. Among several applications in the article, we focus on theta rhythm, a prominent hippocampal oscillation associated with various behavioral correlates and use our computer model to reproduce experimental findings. Finally, we make data, code, and model available through the hippocampushub.eu portal, which also provides an extensive set of analyses of the model and a user-friendly interface to facilitate adoption and usage. This community-based model represents a valuable tool for integrating diverse experimental data and provides a foundation for further research into the complex workings of the hippocampal CA1 region.
- Published
- 2024
- Full Text
- View/download PDF
4. Overflow metabolism provides a selective advantage to Escherichia coli in mixed cultures
- Author
-
Muhammad Yasir, Nicholas M. Thomson, A. Keith Turner, Mark A. Webber, and Ian G. Charles
- Subjects
TraDIS-Xpress ,Mixed acid fermentation ,Competition ,Overflow metabolism ,Warburg effect ,Microbiology ,QR1-502 - Abstract
Abstract Purpose It has previously been shown that organic acids produced by Escherichia coli suppress the growth of Pseudomonas aeruginosa in co-cultures under conditions of glucose excess, due to overflow metabolism. Inactivation of genes involved in central carbon metabolism favours fermentation of glucose over respiration and therefore increases production of organic acid by-products such as acetate and lactate. We sought to extend and refine the list of genes known to contribute to the metabolic balance between respiration and fermentation, to better understand the role of overflow metabolism in competitive survival of E. coli. Methods We confirmed the previous finding that E. coli excludes P. aeruginosa from co-cultures by producing organic acids in the presence of glucose. Using a genome-wide transposon screen we identified E. coli genes that are important for survival in co-cultures with P. aeruginosa, both with and without glucose supplementation. Results Central carbon metabolism was the dominant gene function under selection in our experimental conditions, indicating that the observed inhibition is a side-effect of overflow metabolism adopted by E. coli as a response to high glucose concentrations. The presence of a competing species increased the selective pressure for central carbon metabolism genes, with 31 important for growth in the presence of P. aeruginosa and glucose, while only 9 were significant for pure E. coli cultures grown with glucose. In our experiments, each transposon mutant was competed against all others in the pool, suggesting that overflow metabolism provides benefits to individual E. coli cells in addition to competitive inhibition derived from acidification of the growth medium. Conclusion Co-culture assays using transposon mutant libraries can provide insight into the selective pressures present in mixed species competition. This work demonstrates central carbon metabolism is the dominant gene function under selection in E. coli for aerobic growth in glucose and a side-effect of this is overflow metabolism which can inhibit growth of bystander species.
- Published
- 2024
- Full Text
- View/download PDF
5. Colonisation of hospital surfaces from low- and middle-income countries by extended spectrum β-lactamase- and carbapenemase-producing bacteria
- Author
-
Maria Nieto-Rosado, Kirsty Sands, Edward A. R. Portal, Kathryn M. Thomson, Maria J. Carvalho, Jordan Mathias, Rebecca Milton, Calie Dyer, Chinenye Akpulu, Ian Boostrom, Patrick Hogan, Habiba Saif, Ana D. Sanches Ferreira, Thomas Hender, Barbra Portal, Robert Andrews, W. John Watkins, Rabaab Zahra, Haider Shirazi, Adil Muhammad, Syed Najeeb Ullah, Muhammad Hilal Jan, Shermeen Akif, Kenneth C. Iregbu, Fatima Modibbo, Stella Uwaezuoke, Lamidi Audu, Chinago P. Edwin, Ashiru H. Yusuf, Adeola Adeleye, Aisha S. Mukkadas, Jean Baptiste Mazarati, Aniceth Rucogoza, Lucie Gaju, Shaheen Mehtar, Andrew N. H. Bulabula, Andrew Whitelaw, Lauren Roberts, Grace Chan, Delayehu Bekele, Semaria Solomon, Mahlet Abayneh, Gesit Metaferia, Group BARNARDS, and Timothy R. Walsh
- Subjects
Science - Abstract
Abstract Hospital surfaces can harbour bacterial pathogens, which may disseminate and cause nosocomial infections, contributing towards mortality in low- and middle-income countries (LMICs). During the BARNARDS study, hospital surfaces from neonatal wards were sampled to assess the degree of environmental surface and patient care equipment colonisation by Gram-negative bacteria (GNB) carrying antibiotic resistance genes (ARGs). Here, we perform PCR screening for extended-spectrum β-lactamases (bla CTX-M-15) and carbapenemases (bla NDM, bla OXA-48-like and bla KPC), MALDI-TOF MS identification of GNB carrying ARGs, and further analysis by whole genome sequencing of bacterial isolates. We determine presence of consistently dominant clones and their relatedness to strains causing neonatal sepsis. Higher prevalence of carbapenemases is observed in Pakistan, Bangladesh, and Ethiopia, compared to other countries, and are mostly found in surfaces near the sink drain. Klebsiella pneumoniae, Enterobacter hormaechei, Acinetobacter baumannii, Serratia marcescens and Leclercia adecarboxylata are dominant; ST15 K. pneumoniae is identified from the same ward on multiple occasions suggesting clonal persistence within the same environment, and is found to be identical to isolates causing neonatal sepsis in Pakistan over similar time periods. Our data suggests persistence of dominant clones across multiple time points, highlighting the need for assessment of Infection Prevention and Control guidelines.
- Published
- 2024
- Full Text
- View/download PDF
6. A Web-Based Peer Support Network to Help Care Partners of People With Serious Illness: Co-Design Study
- Author
-
Elizabeth A O’Donnell, Aricca D Van Citters, Inas S Khayal, Matthew M Wilson, David Gustafson, Amber E Barnato, Andrea C Buccellato, Colleen Young, Megan M Holthoff, Eugene Korsunskiy, Stephanie C Tomlin, Amelia M Cullinan, Alexandra C Steinbaugh, Jennifer J Hinson, Kristen R Johnson, Andrew Williams, Ruth M Thomson, Janet M Haines, Anne B Holmes, Ann D Bradley, Eugene C Nelson, and Kathryn B Kirkland
- Subjects
Medical technology ,R855-855.5 - Abstract
BackgroundCare partners of people with serious illness experience significant challenges and unmet needs during the patient’s treatment period and after their death. Learning from others with shared experiences can be valuable, but opportunities are not consistently available. ObjectiveThis study aims to design and prototype a regional, facilitated, and web-based peer support network to help active and bereaved care partners of persons with serious illness be better prepared to cope with the surprises that arise during serious illness and in bereavement. MethodsAn 18-member co-design team included active care partners and those in bereavement, people who had experienced serious illness, regional health care and support partners, and clinicians. It was guided by facilitators and peer network subject-matter experts. We conducted design exercises to identify the functions and specifications of a peer support network. Co-design members independently prioritized network specifications, which were incorporated into an early iteration of the web-based network. ResultsThe team prioritized two functions: (1) connecting care partners to information and (2) facilitating emotional support. The design process generated 24 potential network specifications to support these functions. The highest priorities included providing a supportive and respectful community; connecting people to trusted resources; reducing barriers to asking for help; and providing frequently asked questions and responses. The network platform had to be simple and intuitive, provide technical support for users, protect member privacy, provide publicly available information and a private discussion forum, and be easily accessible. It was feasible to enroll members in the ConnectShareCare web-based network over a 3-month period. ConclusionsA co-design process supported the identification of critical features of a peer support network for care partners of people with serious illnesses in a rural setting, as well as initial testing and use. Further testing is underway to assess the long-term viability and impact of the network.
- Published
- 2024
- Full Text
- View/download PDF
7. Derivation, validation, and comparison of a new prognostic scoring system for acute lower gastrointestinal bleeding
- Author
-
Christopher Smith, Gillian Leggett, Anthoor Jayaprakash, Mohammed Khan, John M. Thomson, Balasubramaniam Vijayan, Andrew Fraser, and John S. Leeds
- Subjects
lower intestinal bleeding ,morbidity ,mortality ,prognosis ,rebleeding ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Objectives Lower gastrointestinal bleeding is a common presentation with little data concerning risk factors for adverse outcomes. The aim was to derive and validate a scoring system to stratify risk in lower gastrointestinal bleeding and compare it to the Oakland score. Methods A total of 2385 consecutive patients (mean age 65 years, 1140 males) were used to derive the score using multivariate logistic regression modeling then internally and externally validated. The Oakland score was applied and area under receiver operating characteristic (AUROC) curves were calculated and compared. A score of
- Published
- 2024
- Full Text
- View/download PDF
8. Short-term impacts of Universal Basic Income on population mental health inequalities in the UK: A microsimulation modelling study.
- Author
-
Rachel M Thomson, Daniel Kopasker, Patryk Bronka, Matteo Richiardi, Vladimir Khodygo, Andrew J Baxter, Erik Igelström, Anna Pearce, Alastair H Leyland, and S Vittal Katikireddi
- Subjects
Medicine - Abstract
BackgroundPopulation mental health in the United Kingdom (UK) has deteriorated, alongside worsening socioeconomic conditions, over the last decade. Policies such as Universal Basic Income (UBI) have been suggested as an alternative economic approach to improve population mental health and reduce health inequalities. UBI may improve mental health (MH), but to our knowledge, no studies have trialled or modelled UBI in whole populations. We aimed to estimate the short-term effects of introducing UBI on mental health in the UK working-age population.Methods and findingsAdults aged 25 to 64 years were simulated across a 4-year period from 2022 to 2026 with the SimPaths microsimulation model, which models the effects of UK tax/benefit policies on mental health via income, poverty, and employment transitions. Data from the nationally representative UK Household Longitudinal Study were used to generate the simulated population (n = 25,000) and causal effect estimates. Three counterfactual UBI scenarios were modelled from 2023: "Partial" (value equivalent to existing benefits), "Full" (equivalent to the UK Minimum Income Standard), and "Full+" (retaining means-tested benefits for disability, housing, and childcare). Likely common mental disorder (CMD) was measured using the General Health Questionnaire (GHQ-12, score ≥4). Relative and slope indices of inequality were calculated, and outcomes stratified by gender, age, education, and household structure. Simulations were run 1,000 times to generate 95% uncertainty intervals (UIs). Sensitivity analyses relaxed SimPaths assumptions about reduced employment resulting from Full/Full+ UBI. Partial UBI had little impact on poverty, employment, or mental health. Full UBI scenarios practically eradicated poverty but decreased employment (for Full+ from 78.9% [95% UI 77.9, 79.9] to 74.1% [95% UI 72.6, 75.4]). Full+ UBI increased absolute CMD prevalence by 0.38% (percentage points; 95% UI 0.13, 0.69) in 2023, equivalent to 157,951 additional CMD cases (95% UI 54,036, 286,805); effects were largest for men (0.63% [95% UI 0.31, 1.01]) and those with children (0.64% [95% UI 0.18, 1.14]). In our sensitivity analysis assuming minimal UBI-related employment impacts, CMD prevalence instead fell by 0.27% (95% UI -0.49, -0.05), a reduction of 112,228 cases (95% UI 20,783, 203,673); effects were largest for women (-0.32% [95% UI -0.65, 0.00]), those without children (-0.40% [95% UI -0.68, -0.15]), and those with least education (-0.42% [95% UI -0.97, 0.15]). There was no effect on educational mental health inequalities in any scenario, and effects waned by 2026. The main limitations of our methods are the model's short time horizon and focus on pathways from UBI to mental health solely via income, poverty, and employment, as well as the inability to integrate macroeconomic consequences of UBI; future iterations of the model will address these limitations.ConclusionsUBI has potential to improve short-term population mental health by reducing poverty, particularly for women, but impacts are highly dependent on whether individuals choose to remain in employment following its introduction. Future research modelling additional causal pathways between UBI and mental health would be beneficial.
- Published
- 2024
- Full Text
- View/download PDF
9. Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides
- Author
-
Olena S. Tokareva, Kunhua Li, Tara L. Travaline, Ty M. Thomson, Jean-Marie Swiecicki, Mahmoud Moussa, Jessica D. Ramirez, Sean Litchman, Gregory L. Verdine, and John H. McGee
- Subjects
Science - Abstract
Abstract Molecules that induce novel interactions between proteins hold great promise for the study of biological systems and the development of therapeutics, but their discovery has been limited by the complexities of rationally designing interactions between three components, and because known binders to each protein are typically required to inform initial designs. Here, we report a general and rapid method for discovering α-helically constrained (Helicon) polypeptides that cooperatively induce the interaction between two target proteins without relying on previously known binders or an intrinsic affinity between the proteins. We show that Helicons are capable of binding every major class of E3 ubiquitin ligases, which are of great biological and therapeutic interest but remain largely intractable to targeting by small molecules. We then describe a phage-based screening method for discovering “trimerizer” Helicons, and apply it to reprogram E3s to cooperatively bind an enzyme (PPIA), a transcription factor (TEAD4), and a transcriptional coactivator (β-catenin).
- Published
- 2023
- Full Text
- View/download PDF
10. A systematic review of the clinical impact of small colony variants in patients with cystic fibrosis
- Author
-
Harrigan Ryan, Emma Ballard, Rebecca E. Stockwell, Christine Duplancic, Rachel M. Thomson, Kimberley Smith, and Scott C. Bell
- Subjects
Small colony variants ,Cystic fibrosis ,Prevalence ,Clinical impact ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Cystic fibrosis (CF) is a life-limiting disorder that is characterised by respiratory tract inflammation that is mediated by a range of microbial pathogens. Small colony variants (SCVs) of common respiratory pathogens are being increasingly recognised in CF. The aim of this systematic review is to investigate the prevalence of SCVs, clinical characteristics and health outcomes for patients with CF, and laboratory diagnostic features of SCVs compared to non-small colony variants (NCVs) for a range of Gram-positive and Gram-negative respiratory pathogens. Methods A literature search was conducted (PubMed, Web of Science, Embase and Scopus) in April 2020 to identify articles of interest. Data pertaining to demographic characteristics of participants, diagnostic criteria of SCVs, SCV prevalence and impact on lung function were extracted from included studies for analysis. Results Twenty-five of 673 studies were included in the systematic review. Individuals infected with SCVs of Staphylococcus aureus (S. aureus) were more likely to have had prior use of the broad-spectrum antibiotic trimethoprim sulfamethoxazole (p
- Published
- 2023
- Full Text
- View/download PDF
11. Effects of Community Assets on Major Health Conditions in England: A Data Analytic Approach
- Author
-
Aristides Moustakas, Linda J. M. Thomson, Rabya Mughal, and Helen J. Chatterjee
- Subjects
data analytics ,multimorbidity ,environmental health ,healthcare ,green space ,community assets ,Medicine - Abstract
Introduction: The broader determinants of health including a wide range of community assets are extremely important in relation to public health outcomes. Multiple health conditions, multimorbidity, is a growing problem in many populations worldwide. Methods: This paper quantified the effect of community assets on major health conditions for the population of England over six years, at a fine spatial scale using a data analytic approach. Community assets, which included indices of the health system, green space, pollution, poverty, urban environment, safety, and sport and leisure facilities, were quantified in relation to major health conditions. The health conditions examined included high blood pressure, obesity, dementia, diabetes, mental health, cardiovascular conditions, musculoskeletal conditions, respiratory conditions, kidney and liver disease, and cancer. Cluster analysis and dendrograms were calculated for the community assets and major health conditions. For each health condition, a statistical model with all community assets was fitted, and model selection was performed. The number of significant community assets for each health condition was recorded. The unique variance, explained by each significant community asset per health condition, was quantified using hierarchical variance partitioning within an analysis of variance model. Results: The resulting data indicate major health conditions are often clustered, as are community assets. The results suggest that diversity and richness of community assets are key to major health condition outcomes. Primary care service waiting times and distance to public parks were significant predictors of all health conditions examined. Primary care waiting times explained the vast majority of the variances across health conditions, with the exception of obesity, which was better explained by absolute poverty. Conclusions: The implications of the combined findings of the health condition clusters and explanatory power of community assets are discussed. The vast majority of determinants of health could be accounted for by healthcare system performance and distance to public green space, with important covariate socioeconomic factors. Emphases on community approaches, significant relationships, and asset strengths and deficits are needed alongside targeted interventions. Whilst the performance of the public health system remains of key importance, community assets and local infrastructure remain paramount to the broader determinants of health.
- Published
- 2024
- Full Text
- View/download PDF
12. Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation
- Author
-
Maria Nuria Peralta-Moreno, Yago Mena, David Ortega-Alarcon, Ana Jimenez-Alesanco, Sonia Vega, Olga Abian, Adrian Velazquez-Campoy, Timothy M. Thomson, Marta Pinto, José M. Granadino-Roldán, Maria Santos Tomas, Juan J. Perez, and Jaime Rubio-Martinez
- Subjects
SARS-CoV-2 main protease ,dark chemical matter ,docking ,molecular dynamics ,MMPB/GBSA approach ,drug design ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The development of specific antiviral therapies targeting SARS-CoV-2 remains fundamental because of the continued high incidence of COVID-19 and limited accessibility to antivirals in some countries. In this context, dark chemical matter (DCM), a set of drug-like compounds with outstanding selectivity profiles that have never shown bioactivity despite being extensively assayed, appears to be an excellent starting point for drug development. Accordingly, in this study, we performed a high-throughput screening to identify inhibitors of the SARS-CoV-2 main protease (Mpro) using DCM compounds as ligands. Multiple receptors and two different docking scoring functions were employed to identify the best molecular docking poses. The selected structures were subjected to extensive conventional and Gaussian accelerated molecular dynamics. From the results, four compounds with the best molecular behavior and binding energy were selected for experimental testing, one of which presented inhibitory activity with a Ki value of 48 ± 5 μM. Through virtual screening, we identified a significant starting point for drug development, shedding new light on DCM compounds.
- Published
- 2024
- Full Text
- View/download PDF
13. Barriers and enablers of integrated care in the UK: a rapid evidence review of review articles and grey literature 2018–2022
- Author
-
Linda J. M. Thomson and Helen J. Chatterjee
- Subjects
barriers ,enablers ,health and social care ,integrated care ,mental health ,multiple morbidities ,Public aspects of medicine ,RA1-1270 - Abstract
Integrated care refers to person-centered and coordinated, health and social care, and community services. Integrated care systems are partnerships of organizations that deliver health and care services which were placed on a statutory footing in England, April 2022. Due to the need for fast, accessible, and relevant evidence, a rapid review was conducted according to World Health Organization methods to determine barriers and enablers of integrated care across the United Kingdom, 2018–2022. Nine databases were searched for review articles reporting evaluation of integrated care interventions involving medical (clinical and diagnostic) and nonmedical (public health services and community-based or social care/person-centred care) approaches, quality checked with the Critical Appraisal Skills Program qualitative checklist. OpenGrey and hand searches were used to identify grey literature, quality checked with the Authority, Accuracy, Coverage, Objectivity, Date, and Significance checklist. Thirty-four reviews and 21 grey literature reports fitted inclusion criteria of adult physical/mental health outcomes/multiple morbidities. Thematic analysis revealed six themes (collaborative approach; costs; evidence and evaluation; integration of care; professional roles; service user factors) with 20 subthemes including key barriers (cost effectiveness; effectiveness of integrated care; evaluation methods; focus of evidence; future research; impact of integration) and enablers (accessing care; collaboration and partnership; concept of integration; inter-professional relationships; person-centered ethos). Findings indicated a paucity of robust research to evaluate such interventions and lack of standardized methodology to assess cost effectiveness, although there is growing interest in co-production that has engendered information sharing and reduced duplication, and inter-professional collaborations that have bridged task-related gaps and overlaps. The importance of identifying elements of integrated care associated with successful outcomes and determining sustainability of interventions meeting joined-up care and preventive population health objectives was highlighted.
- Published
- 2024
- Full Text
- View/download PDF
14. The proteomic fingerprint in infants with single ventricle heart disease in the interstage period: evidence of chronic inflammation and widespread activation of biological networks
- Author
-
Lindsay M. Thomson, Christopher A. Mancuso, Kelly R. Wolfe, Ludmila Khailova, Sierra Niemiec, Eiman Ali, Michael DiMaria, Max Mitchell, Mark Twite, Gareth Morgan, Benjamin S. Frank, and Jesse A. Davidson
- Subjects
biomarkers ,congenital heart disease ,congenital heart defect ,Glenn ,hypoplastic left heart syndrome ,inflammation ,Pediatrics ,RJ1-570 - Abstract
IntroductionChildren with single ventricle heart disease (SVHD) experience significant morbidity across systems and time, with 70% of patients experiencing acute kidney injury, 33% neurodevelopmental impairment, 14% growth failure, and 5.5% of patients suffering necrotizing enterocolitis. Proteomics is a method to identify new biomarkers and mechanisms of injury in complex physiologic states.MethodsInfants with SVHD in the interstage period were compared to similar-age healthy controls. Serum samples were collected, stored at −80°C, and run on a panel of 1,500 proteins in single batch analysis (Somalogic Inc., CO). Partial Least Squares-Discriminant Analysis (PLS-DA) was used to compare the proteomic profile of cases and controls and t-tests to detect differences in individual proteins (FDR 500 circulating proteins distinguishing the groups. These proteomic data identify widespread protein dysregulation across multiple biologic systems with promising biological plausibility as drivers of SVHD morbidity.
- Published
- 2023
- Full Text
- View/download PDF
15. 16p11.2 deletion mice exhibit compromised fronto-temporal connectivity, GABAergic dysfunction, and enhanced attentional ability
- Author
-
Rebecca L. Openshaw, David M. Thomson, Greg C. Bristow, Emma J. Mitchell, Judith A. Pratt, Brian J. Morris, and Neil Dawson
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Abstract Autism spectrum disorders are more common in males, and have a substantial genetic component. Chromosomal 16p11.2 deletions in particular carry strong genetic risk for autism, yet their neurobiological impact is poorly characterised, particularly at the integrated systems level. Here we show that mice reproducing this deletion (16p11.2 DEL mice) have reduced GABAergic interneuron gene expression (decreased parvalbumin mRNA in orbitofrontal cortex, and male-specific decreases in Gad67 mRNA in parietal and insular cortex and medial septum). Metabolic activity was increased in medial septum, and in its efferent targets: mammillary body and (males only) subiculum. Functional connectivity was altered between orbitofrontal, insular and auditory cortex, and between septum and hippocampus/subiculum. Consistent with this circuit dysfunction, 16p11.2 DEL mice showed reduced prepulse inhibition, but enhanced performance in the continuous performance test of attentional ability. Level 1 autistic individuals show similarly heightened performance in the equivalent human test, also associated with parietal, insular-orbitofrontal and septo-subicular dysfunction. The data implicate cortical and septal GABAergic dysfunction, and resulting connectivity changes, as the cause of pre-attentional and attentional changes in autism.
- Published
- 2023
- Full Text
- View/download PDF
16. Concordance between In Vitro and In Vivo Relative Toxic Potencies of Diesel Exhaust Particles from Different Biodiesel Blends
- Author
-
Subramanian Karthikeyan, Dalibor Breznan, Errol M. Thomson, Erica Blais, Renaud Vincent, and Premkumari Kumarathasan
- Subjects
biodiesel ,diesel exhaust particles ,cytotoxicity ,intratracheal instillation ,inflammation ,Chemical technology ,TP1-1185 - Abstract
Diesel exhaust particles (DEPs) contribute to air pollution exposure-related adverse health impacts. Here, we examined in vitro, and in vivo toxicities of DEPs from a Caterpillar C11 heavy-duty diesel engine emissions using ultra-low-sulfur diesel (ULSD) and biodiesel blends (20% v/v) of canola (B20C), soy (B20S), or tallow–waste fry oil (B20T) in ULSD. The in vitro effects of DEPs (DEPULSD, DEPB20C, DEPB20S, and DEPB20T) in exposed mouse monocyte/macrophage cells (J774A.1) were examined by analyzing the cellular cytotoxicity endpoints (CTB, LDH, and ATP) and secreted proteins. The in vivo effects were assessed in BALB/c mice (n = 6/group) exposed to DEPs (250 µg), carbon black (CB), or saline via intratracheal instillation 24 h post-exposure. Bronchoalveolar lavage fluid (BALF) cell counts, cytokines, lung/heart mRNA, and plasma markers were examined. In vitro cytotoxic potencies (e.g., ATP) and secreted TNF-α were positively correlated (p < 0.05) with in vivo inflammatory potency (BALF cytokines, lung/heart mRNA, and plasma markers). Overall, DEPULSD and DEPB20C appeared to be more potent compared to DEPB20S and DEPB20T. These findings suggested that biodiesel blend-derived DEP potencies can be influenced by biodiesel sources, and inflammatory process- was one of the potential underlying toxicity mechanisms. These observations were consistent across in vitro and in vivo exposures, and this work adds value to the health risk analysis of cleaner fuel alternatives.
- Published
- 2024
- Full Text
- View/download PDF
17. Autonomous metabolic reprogramming and oxidative stress characterize endothelial dysfunction in acute myocardial infarction
- Author
-
Erika Zodda, Olga Tura-Ceide, Nicholas L Mills, Josep Tarragó-Celada, Marina Carini, Timothy M Thomson, and Marta Cascante
- Subjects
cardiovascular diseases ,endothelial ,metabolism ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Compelling evidence has accumulated on the role of oxidative stress on the endothelial cell (EC) dysfunction in acute coronary syndrome. Unveiling the underlying metabolic determinants has been hampered by the scarcity of appropriate cell models to address cell-autonomous mechanisms of EC dysfunction. We have generated endothelial cells derived from thrombectomy specimens from patients affected with acute myocardial infarction (AMI) and conducted phenotypical and metabolic characterizations. AMI-derived endothelial cells (AMIECs) display impaired growth, migration, and tubulogenesis. Metabolically, AMIECs displayed augmented ROS and glutathione intracellular content, with a diminished glucose consumption coupled to high lactate production. In AMIECs, while PFKFB3 protein levels of were downregulated, PFKFB4 levels were upregulated, suggesting a shunting of glycolysis towards the pentose phosphate pathway, supported by upregulation of G6PD. Furthermore, the glutaminolytic enzyme GLS was upregulated in AMIECs, providing an explanation for the increase in glutathione content. Finally, AMIECs displayed a significantly higher mitochondrial membrane potential than control ECs, which, together with high ROS levels, suggests a coupled mitochondrial activity. We suggest that high mitochondrial proton coupling underlies the high production of ROS, balanced by PPP- and glutaminolysis-driven synthesis of glutathione, as a primary, cell-autonomous abnormality driving EC dysfunction in AMI.
- Published
- 2023
- Full Text
- View/download PDF
18. Identification of a HIV-1 circulating BF1 recombinant form (CRF75_BF1) of Brazilian origin that also circulates in Southwestern Europe
- Author
-
Joan Bacqué, Elena Delgado, Horacio Gil, Sofía Ibarra, Sonia Benito, Isabel García-Arata, María Moreno-Lorenzo, Ester Sáez de Adana, Carmen Gómez-González, Mónica Sánchez, Vanessa Montero, and Michael M. Thomson
- Subjects
HIV-1 ,circulating recombinant forms ,molecular epidemiology ,phylogeny ,phylodynamics ,recombination ,Microbiology ,QR1-502 - Abstract
IntroductionThe high recombinogenic potential of HIV-1 has resulted in the generation of countless unique recombinant forms (URFs) and around 120 reported circulating recombinant forms (CRFs). Here we identify through analyses of near full-length genomes (NFLG) a new HIV-1 CRF derived from subtypes B and F1.MethodsHIV-1 protease-reverse transcriptase (Pr-RT) sequences were obtained by RT-PCR amplification from plasma RNA. Near full-length genome sequences were obtained after amplification by RT-PCR in 5 overlapping fragments. Phylogenetic sequence analyses were performed via maximum likelihood. Mosaic structures were analyzed by bootscanning and phylogenetic analyses of genome segments. Temporal and geographical estimations of clade emergence were performed with a Bayesian coalescent method.ResultsThrough phylogenetic analyses of HIV-1 Pr-RT sequences obtained by us from samples collected in Spain and downloaded from databases, we identified a BF1 recombinant cluster segregating from previously reported CRFs comprising 52 viruses, most from Brazil (n = 26), Spain (n = 11), and Italy (n = 9). The analyses of NFLG genomes of 4 viruses of the cluster, 2 from Spain and 2 from Italy, allowed to identify a new CRF, designated CRF75_BF1, which exhibits a complex mosaic structure with 20 breakpoints. All 4 patients harboring CRF75_BF1 viruses studied by us had CD4+ T-cell lymphocyte counts below 220/mm3 less than one year after diagnosis, a proportion significantly higher (p = 0.0074) than the 29% found in other patients studied in Spain by us during the same period. The origin of the clade comprising CRF75_BF1 and related viruses was estimated around 1984 in Brazil, with subsequent introduction of CRF75_BF1 in Italy around 1992, and migration from Italy to Spain around 1999.ConclusionA new HIV-1 CRF, designated CRF75_BF1, has been identified. CRF75_BF1 is the 6th CRF of South American origin initially identified in Western Europe, reflecting the increasing relationship of South American and European HIV-1 epidemics. The finding of low CD4+ T-cell lymphocyte counts early after diagnosis in patients harboring CRF75_BF1 viruses warrants further investigation on the virulence of this variant.
- Published
- 2023
- Full Text
- View/download PDF
19. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)Summary
- Author
-
Nicholas T. Ventham, Nicholas A. Kennedy, Rahul Kalla, Alex T. Adams, Alexandra Noble, Holly Ennis, Craig Mowat, Malcolm G. Dunlop, Jack Satsangi, Ian Arnott, Aiden Cahill, Malcolm Smith, Tariq Ahmad, Sreedhar Subramanian, Simon Travis, John Morris, John Hamlin, Anjan Dhar, Chuka Nwokolo, Cathryn Edwards, Tom Creed, Stuart Bloom, Mohamed Yousif, Linzi Thomas, Simon Campbell, Stephen J. Lewis, Shaji Sebastian, Sandip Sen, Simon Lal, Chris Hawkey, Charles Murray, Fraser Cummings, Jason Goh, James O. Lindsay, Naila Arebi, Lindsay Potts, Aileen J. McKinley, John M. Thomson, John A. Todd, Mhairi Collie, Ashley Mowat, Daniel R. Gaya, Jack Winter, Graham D. Naismith, Catriona Keerie, Steff Lewis, Robin J. Prescott, Gordan Lauc, Harry Campbell, Dermot P.B. McGovern, Vito Annese, Vlatka Zoldoš, Iain K. Permberton, Manfred Wuhrer, Daniel Kolarich, Daryl L. Fernandes, Evropi Theorodorou, Victoria Merrick Daniel I. Spencer, Richard A. Gardner, Ray Doran, Archana Shubhakar, Ray Boyapati, Igor Rudan, Paolo Lionetti, Irena Trbojević Akmačić, Jasminka Krištić, Frano Vuč ković, Jerko Štambuk, Mislav Novokmet, Maja Pučić-Baković, Olga Gornik, Angelo Andriulli, Laura Cantoro, Giancarlo Sturniolo, Gionata Fiorino, Natalia Manetti, Anna Latiano, Anna Kohn, Renata D’Inca`, Silvio Danese, Ian D. Arnott, Colin L. Noble, Charlie W. Lees, Alan G. Shand, Gwo-Tzer Ho, Lee Murphy, Jude Gibson, Louise Evenden, Nicola Wrobel, Tamara Gilchrist, Angie Fawkes, Guinevere S.M. Kammeijer, Florent Clerc, Noortje de Haan, Aleksandar Vojta, Ivana Samaržija, Dora Markulin, Marija Klasić, Paula Dobrinić, Yurii Aulchenko, Tim van den Heuve, Daisy Jonkers, and Marieke Pierik
- Subjects
Crohn's disease ,Surgery ,DNA methylation ,Epigenetics ,Inflammatory bowel disease ,Aging ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: DNA methylation alterations may provide important insights into gene-environment interaction in cancer, aging, and complex diseases, such as inflammatory bowel disease (IBD). We aim first to determine whether the circulating DNA methylome in patients requiring surgery may predict Crohn’s disease (CD) recurrence following intestinal resection; and second to compare the circulating methylome seen in patients with established CD with that we had reported in a series of inception cohorts. Methods: TOPPIC was a placebo-controlled, randomized controlled trial of 6-mercaptopurine at 29 UK centers in patients with CD undergoing ileocolic resection between 2008 and 2012. Genomic DNA was extracted from whole blood samples from 229 of the 240 patients taken before intestinal surgery and analyzed using 450KHumanMethylation and Infinium Omni Express Exome arrays (Illumina, San Diego, CA). Coprimary objectives were to determine whether methylation alterations may predict clinical disease recurrence; and to assess whether the epigenetic alterations previously reported in newly diagnosed IBD were present in the patients with CD recruited into the TOPPIC study. Differential methylation and variance analysis was performed comparing patients with and without clinical evidence of recurrence. Secondary analyses included investigation of methylation associations with smoking, genotype (MeQTLs), and chronologic age. Validation of our previously published case-control observation of the methylome was performed using historical control data (CD, n = 123; Control, n = 198). Results: CD recurrence in patients following surgery is associated with 5 differentially methylated positions (Holm P < .05), including probes mapping to WHSC1 (P = 4.1 × 10-9, Holm P = .002) and EFNA3 (P = 4.9 × 10-8, Holm P = .02). Five differentially variable positions are demonstrated in the group of patients with evidence of disease recurrence including a probe mapping to MAD1L1 (P = 6.4 × 10-5). DNA methylation clock analyses demonstrated significant age acceleration in CD compared with control subjects (GrimAge + 2 years; 95% confidence interval, 1.2–2.7 years), with some evidence for accelerated aging in patients with CD with disease recurrence following surgery (GrimAge +1.04 years; 95% confidence interval, -0.04 to 2.22). Significant methylation differences between CD cases and control subjects were seen by comparing this cohort in conjunction with previously published control data, including validation of our previously described differentially methylated positions (RPS6KA2 P = 1.2 × 10-19, SBNO2 = 1.2 × 10-11) and regions (TXK [false discovery rate, P = 3.6 × 10-14], WRAP73 [false discovery rate, P = 1.9 × 10-9], VMP1 [false discovery rate, P = 1.7 × 10-7], and ITGB2 [false discovery rate, P = 1.4 × 10-7]). Conclusions: We demonstrate differential methylation and differentially variable methylation in patients developing clinical recurrence within 3 years of surgery. Moreover, we report replication of the CD-associated methylome, previously characterized only in adult and pediatric inception cohorts, in patients with medically refractory disease needing surgery.
- Published
- 2023
- Full Text
- View/download PDF
20. Evaluation of symmetric dimethylarginine in cats with acute kidney injury and chronic kidney disease
- Author
-
Samantha C. Loane, James M. Thomson, Timothy L. Williams, and Katie E. McCallum
- Subjects
feline ,renal biomarker ,SDMA ,Veterinary medicine ,SF600-1100 - Abstract
Abstract Background Serum symmetric dimethylarginine (SDMA) concentrations are considered a biomarker for renal dysfunction in dogs and humans with acute kidney injury (AKI). No studies have assessed SDMA in cats with AKI. Hypothesis/Objectives SDMA correctly identifies cats with azotemic AKI. Animals Fifteen control cats, 22 with novel AKI, 13 with acute on chronic‐AKI (AoC) and 19 with chronic kidney disease (CKD). Methods Retrospective study. Cats with azotemia (serum creatinine concentrations >1.7 mg/dL) were defined as having AKI or CKD based on history, clinical signs, clinicopathological findings and diagnostic imaging, and classified using the International Renal Interest Society (IRIS) grading/staging systems. Serum SDMA concentrations were compared between groups with nonparametric methods, and correlations assessed using Spearman's correlation coefficient. Data are presented as median [range]. Results SDMA concentrations were 11 (8‐21) μg/dL, 36 (9‐170)μg/dL, 33 (22‐75) μg/dL and 25 (12‐69) μg/dL in control, novel AKI, AoC and CKD cats. SDMA concentrations were significantly higher in cats with novel AKI (P
- Published
- 2022
- Full Text
- View/download PDF
21. On the importance for drug discovery of a transnational Latin American database of natural compound structures
- Author
-
Timothy M. Thomson
- Subjects
natural products ,virtual screening ,Latin America ,databases ,computation ,Therapeutics. Pharmacology ,RM1-950 - Published
- 2023
- Full Text
- View/download PDF
22. Faraday Tomography with CHIME: The 'Tadpole' Feature G137+7
- Author
-
Nasser Mohammed, Anna Ordog, Rebecca A. Booth, Andrea Bracco, Jo-Anne C. Brown, Ettore Carretti, John M. Dickey, Simon Foreman, Mark Halpern, Marijke Haverkorn, Alex S. Hill, Gary Hinshaw, Joseph W. Kania, Roland Kothes, T. L. Landecker, Joshua MacEachern, Kiyoshi W. Masui, Aimee Menard, Ryan R. Ransom, Wolfgang Reich, Patricia Reich, J. Richard Shaw, Seth R. Siegel, Mehrnoosh Tahani, Alec J. M. Thomson, Tristan Pinsonneault-Marotte, Haochen Wang, Jennifer L. West, Maik Wolleben, Dallas Wulf, and CHIME and GMIMS Collaborations
- Subjects
Interstellar medium ,Interstellar magnetic fields ,Stellar-interstellar interactions ,Radio astronomy ,Interstellar dust ,Interstellar clouds ,Astrophysics ,QB460-466 - Abstract
A direct consequence of Faraday rotation is that the polarized radio sky does not resemble the total intensity sky at long wavelengths. We analyze G137+7, which is undetectable in total intensity but appears as a depolarization feature. We use the first polarization maps from the Canadian Hydrogen Intensity Mapping Experiment. Our 400–729 MHz bandwidth and angular resolution, $17^{\prime} $ – $30^{\prime} $ , allow us to use Faraday synthesis to analyze the polarization structure. In polarized intensity and polarization angle maps, we find a tail extending 10° from the head and designate the combined object, the tadpole . Similar polarization angles, distinct from the background, indicate that the head and tail are physically associated. The head appears as a depolarized ring in single channels, but wideband observations show that it is a Faraday rotation feature. Our investigations of H i and H α find no connections to the tadpole. The tail suggests motion of either the gas or an ionizing star through the interstellar medium; the B2(e) star HD 20336 is a candidate. While the head features a coherent, ∼ −8 rad m ^−2 Faraday depth, Faraday synthesis also identifies multiple components in both the head and tail. We verify the locations of the components in the spectra using QU fitting. Our results show that approximately octave-bandwidth Faraday rotation observations at ∼600 MHz are sensitive to low-density ionized or partially ionized gas, which is undetectable in other tracers.
- Published
- 2024
- Full Text
- View/download PDF
23. Prototype Faraday Rotation Measure Catalogs from the Polarisation Sky Survey of the Universe’s Magnetism (POSSUM) Pilot Observations
- Author
-
S. Vanderwoude, J. L. West, B. M. Gaensler, L. Rudnick, C. L. Van Eck, A. J. M. Thomson, H. Andernach, C. S. Anderson, E. Carretti, G. H. Heald, J. P. Leahy, N. M. McClure-Griffiths, S. P. O’Sullivan, M. Tahani, and A. G. Willis
- Subjects
Sky surveys ,Catalogs ,Spectropolarimetry ,Polarimetry ,Astrophysical magnetism ,Galaxy magnetic fields ,Astronomy ,QB1-991 - Abstract
The Polarisation Sky Survey of the Universe’s Magnetism (POSSUM) will conduct a sensitive ∼1 GHz radio polarization survey covering 20,000 deg ^2 of the southern sky with the Australian Square Kilometre Array Pathfinder. In anticipation of the full survey, we analyze pilot observations of low-band (800–1087 MHz), mid-band (1316–1439 MHz), and combined-band observations for an extragalactic field and a Galactic plane field (low-band only). Using the POSSUM processing pipeline, we produce prototype rotation measure (RM) catalogs that are filtered to construct prototype RM grids. We assess typical RM grid densities and RM uncertainties and their dependence on frequency, bandwidth, and Galactic latitude. We present a median filter method for separating foreground diffuse emission from background components and find that after application of the filter, 99.5% of the measured RMs of simulated sources are within 3 σ of their true RM, with a typical loss of polarized intensity of 5% ± 5%. We find RM grid densities of 35.1, 30.6, 37.2, and 13.5 RMs per square degree and median uncertainties on RM measurements of 1.55, 12.82, 1.06, and 1.89 rad m ^−2 for the median-filtered low-band, mid-band, combined-band, and Galactic observations, respectively. We estimate that the full POSSUM survey will produce an RM catalog of ∼775,000 RMs with median-filtered low-band observations and ∼877,000 RMs with median-filtered combined-band observations. We construct a structure function from the Galactic RM catalog, which shows a break at 0.°7, corresponding to a physical scale of 12–24 pc for the nearest spiral arm.
- Published
- 2024
- Full Text
- View/download PDF
24. Concurrent validity of the short-form Family Impact Scale (FIS-8) in 4-year-old US children
- Author
-
W. M. Thomson, L. A. Foster Page, S. M. Levy, M. A. Keels, A. T. Hara, and M. Fontana
- Subjects
Quality of Life ,Child ,Family ,Oral Health ,Pediatrics ,RJ1-570 - Abstract
Abstract Background US data on the validity and reliability of the short-form Family Impact Scale (FIS-8; a scale for measuring the impact of a child’s oral condition on his/her family) are lacking. Methods Cross-sectional analysis of data on four-year-old US children taking part in a multi-center cohort study. For child-caregiver dyads recruited at child age 12 months, the impact of the child’s oral condition on the family was assessed at age 48 months using the FIS-8, with a subsample of 422 caregivers (from 686 who were approached). Internal consistency reliability was assessed using Cronbach’s α, with concurrent validity assessed against a global family impact item (“How much are your family’s daily lives affected by your child’s teeth, lips, jaws or mouth?”) and a global oral health item (“How would you describe the health of your child’s teeth and mouth?”). Results Cronbach’s alpha was 0.83. Although gradients in mean scores across ordinal response categories of the global family impact item were inconsistent, there were marked, consistent gradients across the ordinal categories of the global item on the child’s oral health, with scores highest for those rating their child’s oral health as ‘Poor’. Conclusions While the findings provide some evidence for the utility of the FIS in a US child sample, the study’s replication in samples of preschoolers with greater disease experience would be useful.
- Published
- 2022
- Full Text
- View/download PDF
25. Clinical Outcomes of Stereotactic Radiosurgery-Related Radiation Necrosis in Patients with Intracranial Metastasis from Melanoma
- Author
-
Holly M Thomson, Shannon P Fortin Ensign, Victoria S Edmonds, Akanksha Sharma, Richard J Butterfield, Steven E Schild, Jonathan B Ashman, Richard S Zimmerman, Naresh P Patel, Alan H Bryce, Sujay A Vora, Terence T Sio, and Alyx B Porter
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Radiation necrosis (RN) is a clinically relevant complication of stereotactic radiosurgery (SRS) for intracranial metastasis (ICM) treatments. Radiation necrosis development is variable following SRS. It remains unclear if risk factors for and clinical outcomes following RN may be different for melanoma patients. We reviewed patients with ICM from metastatic melanoma to understand the potential impact of RN in this patient population. Methods: Patients who received SRS for ICM from melanoma at Mayo Clinic Arizona between 2013 and 2018 were retrospectively reviewed. Data collected included demographics, tumor characteristics, radiation parameters, prior surgical and systemic treatments, and patient outcomes. Radiation necrosis was diagnosed by clinical evaluation including brain magnetic resonance imaging (MRI) and, in some cases, tissue evaluation. Results: Radiation necrosis was diagnosed in 7 (27%) of 26 patients at 1.6 to 38 months following initial SRS. Almost 92% of all patients received systemic therapy and 35% had surgical resection prior to SRS. Patients with RN trended toward having larger ICM and a prior history of surgical resection, although statistical significance was not reached. Among patients with resection, those who developed RN had a longer period between surgery and SRS start (mean 44 vs 33 days). Clinical improvement following treatment for RN was noted in 2 (29%) patients. Conclusions: Radiation necrosis is relatively common following SRS for treatment of ICM from metastatic melanoma and clinical outcomes are poor. Further studies aimed at mitigating RN development and identifying novel approaches for treatment are warranted.
- Published
- 2023
- Full Text
- View/download PDF
26. Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients
- Author
-
Emily Toscano-Guerra, Mónica Martínez Gallo, Iria Arrese-Muñoz, Anna Giné, Noelia Díaz-Troyano, Pablo Gabriel-Medina, Mar Riveiro-Barciela, Moisés Labrador-Horrillo, Fernando Martinez-Valle, Adrián Sánchez Montalvá, Manuel Hernández-González, Ricardo Pujol Borrell, Francisco Rodríguez-Frias, Roser Ferrer, Timothy M. Thomson, and Rosanna Paciucci
- Subjects
COVID-19 ,Survival ,Longitudinal ,Testosterone ,Immune phenotype ,Medicine - Abstract
Abstract Background SARS-CoV-2 infection portends a broad range of outcomes, from a majority of asymptomatic cases to a lethal disease. Robust correlates of severe COVID-19 include old age, male sex, poverty, and co-morbidities such as obesity, diabetes, and cardiovascular disease. A precise knowledge of the molecular and biological mechanisms that may explain the association of severe disease with male sex is still lacking. Here, we analyzed the relationship of serum testosterone levels and the immune cell skewing with disease severity in male COVID-19 patients. Methods Biochemical and hematological parameters of admission samples in 497 hospitalized male and female COVID-19 patients, analyzed for associations with outcome and sex. Longitudinal (in-hospital course) analyses of a subcohort of 114 male patients were analyzed for associations with outcome. Longitudinal analyses of immune populations by flow cytometry in 24 male patients were studied for associations with outcome. Results We have found quantitative differences in biochemical predictors of disease outcome in male vs. female patients. Longitudinal analyses in a subcohort of male COVID-19 patients identified serum testosterone trajectories as the strongest predictor of survival (AUC of ROC = 92.8%, p < 0.0001) in these patients among all biochemical parameters studied, including single-point admission serum testosterone values. In lethal cases, longitudinal determinations of serum luteinizing hormone (LH) and androstenedione levels did not follow physiological feedback patterns. Failure to reinstate physiological testosterone levels was associated with evidence of impaired T helper differentiation and augmented circulating classical monocytes. Conclusions Recovery or failure to reinstate testosterone levels is strongly associated with survival or death, respectively, from COVID-19 in male patients. Our data suggest an early inhibition of the central LH-androgen biosynthesis axis in a majority of patients, followed by full recovery in survivors or a peripheral failure in lethal cases. These observations are suggestive of a significant role of testosterone status in the immune responses to COVID-19 and warrant future experimental explorations of mechanistic relationships between testosterone status and SARS-CoV-2 infection outcomes, with potential prophylactic or therapeutic implications.
- Published
- 2022
- Full Text
- View/download PDF
27. CD161 expression defines new human γδ T cell subsets
- Author
-
Amali Karunathilaka, Samuel Halstrom, Patricia Price, Michael Holt, Viviana P. Lutzky, Denise L. Doolan, Andreas Kupz, Scott C. Bell, Rachel M. Thomson, John J. Miles, and Champa N. Ratnatunga
- Subjects
Cellular immunity ,CD161 ,γδ T cell ,γδ T cell subsets ,γδ T cell multifunctionality ,High dimensional flow cytometry ,Immunologic diseases. Allergy ,RC581-607 ,Geriatrics ,RC952-954.6 - Abstract
Abstract γδ T cells are a highly versatile immune lineage involved in host defense and homeostasis, but questions remain around their heterogeneity, precise function and role during health and disease. We used multi−parametric flow cytometry, dimensionality reduction, unsupervised clustering, and self-organizing maps (SOM) to identify novel γδ T cell naïve/memory subsets chiefly defined by CD161 expression levels, a surface membrane receptor that can be activating or suppressive. We used middle-to-old age individuals given immune blockade is commonly used in this population. Whilst most Vδ1+subset cells exhibited a terminal differentiation phenotype, Vδ1− subset cells showed an early memory phenotype. Dimensionality reduction revealed eight γδ T cell clusters chiefly diverging through CD161 expression with CD4 and CD8 expression limited to specific subpopulations. Comparison of matched healthy elderly individuals to bronchiectasis patients revealed elevated Vδ1+ terminally differentiated effector memory cells in patients potentially linking this population with chronic proinflammatory disease.
- Published
- 2022
- Full Text
- View/download PDF
28. Erratum to: Search for single top-quark production via flavour-changing neutral currents at 8 TeV with the ATLAS detector
- Author
-
G. Aad, B. Abbott, J. Abdallah, O. Abdinov, R. Aben, M. Abolins, O. S. AbouZeid, H. Abramowicz, H. Abreu, R. Abreu, Y. Abulaiti, B. S. Acharya, L. Adamczyk, D. L. Adams, J. Adelman, S. Adomeit, T. Adye, A. A. Affolder, T. Agatonovic-Jovin, J. Agricola, J. A. Aguilar-Saavedra, S. P. Ahlen, F. Ahmadov, G. Aielli, H. Akerstedt, T. P. A. Åkesson, A. V. Akimov, G. L. Alberghi, J. Albert, S. Albrand, M. J. Alconada Verzini, M. Aleksa, I. N. Aleksandrov, C. Alexa, G. Alexander, T. Alexopoulos, M. Alhroob, G. Alimonti, L. Alio, J. Alison, S. P. Alkire, B. M. M. Allbrooke, P. P. Allport, A. Aloisio, A. Alonso, F. Alonso, C. Alpigiani, A. Altheimer, B. Alvarez Gonzalez, D. Álvarez Piqueras, M. G. Alviggi, B. T. Amadio, K. Amako, Y. Amaral Coutinho, C. Amelung, D. Amidei, S. P. Amor Dos Santos, A. Amorim, S. Amoroso, N. Amram, G. Amundsen, C. Anastopoulos, L. S. Ancu, N. Andari, T. Andeen, C. F. Anders, G. Anders, J. K. Anders, K. J. Anderson, A. Andreazza, V. Andrei, S. Angelidakis, I. Angelozzi, P. Anger, A. Angerami, F. Anghinolfi, A. V. Anisenkov, N. Anjos, A. Annovi, M. Antonelli, A. Antonov, J. Antos, F. Anulli, M. Aoki, L. Aperio Bella, G. Arabidze, Y. Arai, J. P. Araque, A. T. H. Arce, F. A. Arduh, J-F. Arguin, S. Argyropoulos, M. Arik, A. J. Armbruster, O. Arnaez, V. Arnal, H. Arnold, M. Arratia, O. Arslan, A. Artamonov, G. Artoni, S. Asai, N. Asbah, A. Ashkenazi, B. Åsman, L. Asquith, K. Assamagan, R. Astalos, M. Atkinson, N. B. Atlay, K. Augsten, M. Aurousseau, G. Avolio, B. Axen, M. K. Ayoub, G. Azuelos, M. A. Baak, A. E. Baas, M. J. Baca, C. Bacci, H. Bachacou, K. Bachas, M. Backes, M. Backhaus, P. Bagiacchi, P. Bagnaia, Y. Bai, T. Bain, J. T. Baines, O. K. Baker, E. M. Baldin, P. Balek, T. Balestri, F. Balli, E. Banas, Sw. Banerjee, A. A. E. Bannoura, H. S. Bansil, L. Barak, E. L. Barberio, D. Barberis, M. Barbero, T. Barillari, M. Barisonzi, T. Barklow, N. Barlow, S. L. Barnes, B. M. Barnett, R. M. Barnett, Z. Barnovska, A. Baroncelli, G. Barone, A. J. Barr, F. Barreiro, J. Barreiro Guimarães da Costa, R. Bartoldus, A. E. Barton, P. Bartos, A. Basalaev, A. Bassalat, A. Basye, R. L. Bates, S. J. Batista, J. R. Batley, M. Battaglia, M. Bauce, F. Bauer, H. S. Bawa, J. B. Beacham, M. D. Beattie, T. Beau, P. H. Beauchemin, R. Beccherle, P. Bechtle, H. P. Beck, K. Becker, M. Becker, M. Beckingham, C. Becot, A. J. Beddall, A. Beddall, V. A. Bednyakov, C. P. Bee, L. J. Beemster, T. A. Beermann, M. Begel, J. K. Behr, C. Belanger-Champagne, W. H. Bell, G. Bella, L. Bellagamba, A. Bellerive, M. Bellomo, K. Belotskiy, O. Beltramello, O. Benary, D. Benchekroun, M. Bender, K. Bendtz, N. Benekos, Y. Benhammou, E. Benhar Noccioli, J. A. Benitez Garcia, D. P. Benjamin, J. R. Bensinger, S. Bentvelsen, L. Beresford, M. Beretta, D. Berge, E. Bergeaas Kuutmann, N. Berger, F. Berghaus, J. Beringer, C. Bernard, N. R. Bernard, C. Bernius, F. U. Bernlochner, T. Berry, P. Berta, C. Bertella, G. Bertoli, F. Bertolucci, C. Bertsche, D. Bertsche, M. I. Besana, G. J. Besjes, O. Bessidskaia Bylund, M. Bessner, N. Besson, C. Betancourt, S. Bethke, A. J. Bevan, W. Bhimji, R. M. Bianchi, L. Bianchini, M. Bianco, O. Biebel, D. Biedermann, S. P. Bieniek, M. Biglietti, J. Bilbao De Mendizabal, H. Bilokon, M. Bindi, S. Binet, A. Bingul, C. Bini, S. Biondi, C. W. Black, J. E. Black, K. M. Black, D. Blackburn, R. E. Blair, J.-B. Blanchard, J. E. Blanco, T. Blazek, I. Bloch, C. Blocker, W. Blum, U. Blumenschein, G. J. Bobbink, V. S. Bobrovnikov, S. S. Bocchetta, A. Bocci, C. Bock, M. Boehler, J. A. Bogaerts, D. Bogavac, A. G. Bogdanchikov, C. Bohm, V. Boisvert, T. Bold, V. Boldea, A. S. Boldyrev, M. Bomben, M. Bona, M. Boonekamp, A. Borisov, G. Borissov, S. Borroni, J. Bortfeldt, V. Bortolotto, K. Bos, D. Boscherini, M. Bosman, J. Boudreau, J. Bouffard, E. V. Bouhova-Thacker, D. Boumediene, C. Bourdarios, N. Bousson, A. Boveia, J. Boyd, I. R. Boyko, I. Bozic, J. Bracinik, A. Brandt, G. Brandt, O. Brandt, U. Bratzler, B. Brau, J. E. Brau, H. M. Braun, S. F. Brazzale, W. D. Breaden Madden, K. Brendlinger, A. J. Brennan, L. Brenner, R. Brenner, S. Bressler, K. Bristow, T. M. Bristow, D. Britton, D. Britzger, F. M. Brochu, I. Brock, R. Brock, J. Bronner, G. Brooijmans, T. Brooks, W. K. Brooks, J. Brosamer, E. Brost, J. Brown, P. A. Bruckman de Renstrom, D. Bruncko, R. Bruneliere, A. Bruni, G. Bruni, M. Bruschi, N. Bruscino, L. Bryngemark, T. Buanes, Q. Buat, P. Buchholz, A. G. Buckley, S. I. Buda, I. A. Budagov, F. Buehrer, L. Bugge, M. K. Bugge, O. Bulekov, D. Bullock, H. Burckhart, S. Burdin, C. D. Burgard, B. Burghgrave, S. Burke, I. Burmeister, E. Busato, D. Büscher, V. Büscher, P. Bussey, J. M. Butler, A. I. Butt, C. M. Buttar, J. M. Butterworth, P. Butti, W. Buttinger, A. Buzatu, A. R. Buzykaev, S. Cabrera Urbán, D. Caforio, V. M. Cairo, O. Cakir, N. Calace, P. Calafiura, A. Calandri, G. Calderini, P. Calfayan, L. P. Caloba, D. Calvet, S. Calvet, R. Camacho Toro, S. Camarda, P. Camarri, D. Cameron, R. Caminal Armadans, S. Campana, M. Campanelli, A. Campoverde, V. Canale, A. Canepa, M. Cano Bret, J. Cantero, R. Cantrill, T. Cao, M. D. M. Capeans Garrido, I. Caprini, M. Caprini, M. Capua, R. Caputo, R. Cardarelli, F. Cardillo, T. Carli, G. Carlino, L. Carminati, S. Caron, E. Carquin, G. D. Carrillo-Montoya, J. R. Carter, J. Carvalho, D. Casadei, M. P. Casado, M. Casolino, E. Castaneda-Miranda, A. Castelli, V. Castillo Gimenez, N. F. Castro, P. Catastini, A. Catinaccio, J. R. Catmore, A. Cattai, J. Caudron, V. Cavaliere, D. Cavalli, M. Cavalli-Sforza, V. Cavasinni, F. Ceradini, B. C. Cerio, K. Cerny, A. S. Cerqueira, A. Cerri, L. Cerrito, F. Cerutti, M. Cerv, A. Cervelli, S. A. Cetin, A. Chafaq, D. Chakraborty, I. Chalupkova, P. Chang, J. D. Chapman, D. G. Charlton, C. C. Chau, C. A. Chavez Barajas, S. Cheatham, A. Chegwidden, S. Chekanov, S. V. Chekulaev, G. A. Chelkov, M. A. Chelstowska, C. Chen, H. Chen, K. Chen, L. Chen, S. Chen, X. Chen, Y. Chen, H. C. Cheng, Y. Cheng, A. Cheplakov, E. Cheremushkina, R. Cherkaoui El Moursli, V. Chernyatin, E. Cheu, L. Chevalier, V. Chiarella, G. Chiarelli, G. Chiodini, A. S. Chisholm, R. T. Chislett, A. Chitan, M. V. Chizhov, K. Choi, S. Chouridou, B. K. B. Chow, V. Christodoulou, D. Chromek-Burckhart, J. Chudoba, A. J. Chuinard, J. J. Chwastowski, L. Chytka, G. Ciapetti, A. K. Ciftci, D. Cinca, V. Cindro, I. A. Cioara, A. Ciocio, F. Cirotto, Z. H. Citron, M. Ciubancan, A. Clark, B. L. Clark, P. J. Clark, R. N. Clarke, W. Cleland, C. Clement, Y. Coadou, M. Cobal, A. Coccaro, J. Cochran, L. Coffey, J. G. Cogan, L. Colasurdo, B. Cole, S. Cole, A. P. Colijn, J. Collot, T. Colombo, G. Compostella, P. Conde Muiño, E. Coniavitis, S. H. Connell, I. A. Connelly, V. Consorti, S. Constantinescu, C. Conta, G. Conti, F. Conventi, M. Cooke, B. D. Cooper, A. M. Cooper-Sarkar, T. Cornelissen, M. Corradi, F. Corriveau, A. Corso-Radu, A. Cortes-Gonzalez, G. Cortiana, G. Costa, M. J. Costa, D. Costanzo, D. Côté, G. Cottin, G. Cowan, B. E. Cox, K. Cranmer, G. Cree, S. Crépé-Renaudin, F. Crescioli, W. A. Cribbs, M. Crispin Ortuzar, M. Cristinziani, V. Croft, G. Crosetti, T. Cuhadar Donszelmann, J. Cummings, M. Curatolo, C. Cuthbert, H. Czirr, P. Czodrowski, S. D’Auria, M. D’Onofrio, M. J. Da Cunha Sargedas De Sousa, C. Da Via, W. Dabrowski, A. Dafinca, T. Dai, O. Dale, F. Dallaire, C. Dallapiccola, M. Dam, J. R. Dandoy, N. P. Dang, A. C. Daniells, M. Danninger, M. Dano Hoffmann, V. Dao, G. Darbo, S. Darmora, J. Dassoulas, A. Dattagupta, W. Davey, C. David, T. Davidek, E. Davies, M. Davies, P. Davison, Y. Davygora, E. Dawe, I. Dawson, R. K. Daya-Ishmukhametova, K. De, R. de Asmundis, A. De Benedetti, S. De Castro, S. De Cecco, N. De Groot, P. de Jong, H. De la Torre, F. De Lorenzi, D. De Pedis, A. De Salvo, U. De Sanctis, A. De Santo, J. B. De Vivie De Regie, W. J. Dearnaley, R. Debbe, C. Debenedetti, D. V. Dedovich, I. Deigaard, J. Del Peso, T. Del Prete, D. Delgove, F. Deliot, C. M. Delitzsch, M. Deliyergiyev, A. Dell’Acqua, L. Dell’Asta, M. Dell’Orso, M. Della Pietra, D. della Volpe, M. Delmastro, P. A. Delsart, C. Deluca, D. A. DeMarco, S. Demers, M. Demichev, A. Demilly, S. P. Denisov, D. Derendarz, J. E. Derkaoui, F. Derue, P. Dervan, K. Desch, C. Deterre, P. O. Deviveiros, A. Dewhurst, S. Dhaliwal, A. Di Ciaccio, L. Di Ciaccio, A. Di Domenico, C. Di Donato, A. Di Girolamo, B. Di Girolamo, A. Di Mattia, B. Di Micco, R. Di Nardo, A. Di Simone, R. Di Sipio, D. Di Valentino, C. Diaconu, M. Diamond, F. A. Dias, M. A. Diaz, E. B. Diehl, J. Dietrich, S. Diglio, A. Dimitrievska, J. Dingfelder, P. Dita, S. Dita, F. Dittus, F. Djama, T. Djobava, J. I. Djuvsland, M. A. B. do Vale, D. Dobos, M. Dobre, C. Doglioni, T. Dohmae, J. Dolejsi, Z. Dolezal, B. A. Dolgoshein, M. Donadelli, S. Donati, P. Dondero, J. Donini, J. Dopke, A. Doria, M. T. Dova, A. T. Doyle, E. Drechsler, M. Dris, E. Dubreuil, E. Duchovni, G. Duckeck, O. A. Ducu, D. Duda, A. Dudarev, L. Duflot, L. Duguid, M. Dührssen, M. Dunford, H. Duran Yildiz, M. Düren, A. Durglishvili, D. Duschinger, M. Dyndal, C. Eckardt, K. M. Ecker, R. C. Edgar, W. Edson, N. C. Edwards, W. Ehrenfeld, T. Eifert, G. Eigen, K. Einsweiler, T. Ekelof, M. El Kacimi, M. Ellert, S. Elles, F. Ellinghaus, A. A. Elliot, N. Ellis, J. Elmsheuser, M. Elsing, D. Emeliyanov, Y. Enari, O. C. Endner, M. Endo, J. Erdmann, A. Ereditato, G. Ernis, J. Ernst, M. Ernst, S. Errede, E. Ertel, M. Escalier, H. Esch, C. Escobar, B. Esposito, A. I. Etienvre, E. Etzion, H. Evans, A. Ezhilov, L. Fabbri, G. Facini, R. M. Fakhrutdinov, S. Falciano, R. J. Falla, J. Faltova, Y. Fang, M. Fanti, A. Farbin, A. Farilla, T. Farooque, S. Farrell, S. M. Farrington, P. Farthouat, F. Fassi, P. Fassnacht, D. Fassouliotis, M. Faucci Giannelli, A. Favareto, L. Fayard, P. Federic, O. L. Fedin, W. Fedorko, S. Feigl, L. Feligioni, C. Feng, E. J. Feng, H. Feng, A. B. Fenyuk, L. Feremenga, P. Fernandez Martinez, S. Fernandez Perez, J. Ferrando, A. Ferrari, P. Ferrari, R. Ferrari, D. E. Ferreira de Lima, A. Ferrer, D. Ferrere, C. Ferretti, A. Ferretto Parodi, M. Fiascaris, F. Fiedler, A. Filipčič, M. Filipuzzi, F. Filthaut, M. Fincke-Keeler, K. D. Finelli, M. C. N. Fiolhais, L. Fiorini, A. Firan, A. Fischer, C. Fischer, J. Fischer, W. C. Fisher, E. A. Fitzgerald, N. Flaschel, I. Fleck, P. Fleischmann, S. Fleischmann, G. T. Fletcher, G. Fletcher, R. R. M. Fletcher, T. Flick, A. Floderus, L. R. Flores Castillo, M. J. Flowerdew, A. Formica, A. Forti, D. Fournier, H. Fox, S. Fracchia, P. Francavilla, M. Franchini, D. Francis, L. Franconi, M. Franklin, M. Frate, M. Fraternali, D. Freeborn, S. T. French, F. Friedrich, D. Froidevaux, J. A. Frost, C. Fukunaga, E. Fullana Torregrosa, B. G. Fulsom, T. Fusayasu, J. Fuster, C. Gabaldon, O. Gabizon, A. Gabrielli, G. P. Gach, S. Gadatsch, S. Gadomski, G. Gagliardi, P. Gagnon, C. Galea, B. Galhardo, E. J. Gallas, B. J. Gallop, P. Gallus, G. Galster, K. K. Gan, J. Gao, Y. Gao, Y. S. Gao, F. M. Garay Walls, F. Garberson, C. García, J. E. García Navarro, M. Garcia-Sciveres, R. W. Gardner, N. Garelli, V. Garonne, C. Gatti, A. Gaudiello, G. Gaudio, B. Gaur, L. Gauthier, P. Gauzzi, I. L. Gavrilenko, C. Gay, G. Gaycken, E. N. Gazis, P. Ge, Z. Gecse, C. N. P. Gee, Ch. Geich-Gimbel, M. P. Geisler, C. Gemme, M. H. Genest, S. Gentile, M. George, S. George, D. Gerbaudo, A. Gershon, S. Ghasemi, H. Ghazlane, B. Giacobbe, S. Giagu, V. Giangiobbe, P. Giannetti, B. Gibbard, S. M. Gibson, M. Gilchriese, T. P. S. Gillam, D. Gillberg, G. Gilles, D. M. Gingrich, N. Giokaris, M. P. Giordani, F. M. Giorgi, P. F. Giraud, P. Giromini, D. Giugni, C. Giuliani, M. Giulini, B. K. Gjelsten, S. Gkaitatzis, I. Gkialas, E. L. Gkougkousis, L. K. Gladilin, C. Glasman, J. Glatzer, P. C. F. Glaysher, A. Glazov, M. Goblirsch-Kolb, J. R. Goddard, J. Godlewski, S. Goldfarb, T. Golling, D. Golubkov, A. Gomes, R. Gonçalo, J. Goncalves Pinto Firmino Da Costa, L. Gonella, S. González de la Hoz, G. Gonzalez Parra, S. Gonzalez-Sevilla, L. Goossens, P. A. Gorbounov, H. A. Gordon, I. Gorelov, B. Gorini, E. Gorini, A. Gorišek, E. Gornicki, A. T. Goshaw, C. Gössling, M. I. Gostkin, D. Goujdami, A. G. Goussiou, N. Govender, E. Gozani, H. M. X. Grabas, L. Graber, I. Grabowska-Bold, P. O. J. Gradin, P. Grafström, K-J. Grahn, J. Gramling, E. Gramstad, S. Grancagnolo, V. Gratchev, H. M. Gray, E. Graziani, Z. D. Greenwood, C. Grefe, K. Gregersen, I. M. Gregor, P. Grenier, J. Griffiths, A. A. Grillo, K. Grimm, S. Grinstein, Ph. Gris, J.-F. Grivaz, J. P. Grohs, A. Grohsjean, E. Gross, J. Grosse-Knetter, G. C. Grossi, Z. J. Grout, L. Guan, J. Guenther, F. Guescini, D. Guest, O. Gueta, E. Guido, T. Guillemin, S. Guindon, U. Gul, C. Gumpert, J. Guo, Y. Guo, S. Gupta, G. Gustavino, P. Gutierrez, N. G. Gutierrez Ortiz, C. Gutschow, C. Guyot, C. Gwenlan, C. B. Gwilliam, A. Haas, C. Haber, H. K. Hadavand, N. Haddad, P. Haefner, S. Hageböck, Z. Hajduk, H. Hakobyan, M. Haleem, J. Haley, D. Hall, G. Halladjian, G. D. Hallewell, K. Hamacher, P. Hamal, K. Hamano, A. Hamilton, G. N. Hamity, P. G. Hamnett, L. Han, K. Hanagaki, K. Hanawa, M. Hance, P. Hanke, R. Hanna, J. B. Hansen, J. D. Hansen, M. C. Hansen, P. H. Hansen, K. Hara, A. S. Hard, T. Harenberg, F. Hariri, S. Harkusha, R. D. Harrington, P. F. Harrison, F. Hartjes, M. Hasegawa, Y. Hasegawa, A. Hasib, S. Hassani, S. Haug, R. Hauser, L. Hauswald, M. Havranek, C. M. Hawkes, R. J. Hawkings, A. D. Hawkins, T. Hayashi, D. Hayden, C. P. Hays, J. M. Hays, H. S. Hayward, S. J. Haywood, S. J. Head, T. Heck, V. Hedberg, L. Heelan, S. Heim, T. Heim, B. Heinemann, L. Heinrich, J. Hejbal, L. Helary, S. Hellman, D. Hellmich, C. Helsens, J. Henderson, R. C. W. Henderson, Y. Heng, C. Hengler, S. Henkelmann, A. Henrichs, A. M. Henriques Correia, S. Henrot-Versille, G. H. Herbert, Y. Hernández Jiménez, R. Herrberg-Schubert, G. Herten, R. Hertenberger, L. Hervas, G. G. Hesketh, N. P. Hessey, J. W. Hetherly, R. Hickling, E. Higón-Rodriguez, E. Hill, J. C. Hill, K. H. Hiller, S. J. Hillier, I. Hinchliffe, E. Hines, R. R. Hinman, M. Hirose, D. Hirschbuehl, J. Hobbs, N. Hod, M. C. Hodgkinson, P. Hodgson, A. Hoecker, M. R. Hoeferkamp, F. Hoenig, M. Hohlfeld, D. Hohn, T. R. Holmes, M. Homann, T. M. Hong, L. Hooft van Huysduynen, W. H. Hopkins, Y. Horii, A. J. Horton, J-Y. Hostachy, S. Hou, A. Hoummada, J. Howard, J. Howarth, M. Hrabovsky, I. Hristova, J. Hrivnac, T. Hryn’ova, A. Hrynevich, C. Hsu, P. J. Hsu, S.-C. Hsu, D. Hu, Q. Hu, X. Hu, Y. Huang, Z. Hubacek, F. Hubaut, F. Huegging, T. B. Huffman, E. W. Hughes, G. Hughes, M. Huhtinen, T. A. Hülsing, N. Huseynov, J. Huston, J. Huth, G. Iacobucci, G. Iakovidis, I. Ibragimov, L. Iconomidou-Fayard, E. Ideal, Z. Idrissi, P. Iengo, O. Igonkina, T. Iizawa, Y. Ikegami, K. Ikematsu, M. Ikeno, Y. Ilchenko, D. Iliadis, N. Ilic, T. Ince, G. Introzzi, P. Ioannou, M. Iodice, K. Iordanidou, V. Ippolito, A. Irles Quiles, C. Isaksson, M. Ishino, M. Ishitsuka, R. Ishmukhametov, C. Issever, S. Istin, J. M. Iturbe Ponce, R. Iuppa, J. Ivarsson, W. Iwanski, H. Iwasaki, J. M. Izen, V. Izzo, S. Jabbar, B. Jackson, M. Jackson, P. Jackson, M. R. Jaekel, V. Jain, K. Jakobs, S. Jakobsen, T. Jakoubek, J. Jakubek, D. O. Jamin, D. K. Jana, E. Jansen, R. Jansky, J. Janssen, M. Janus, G. Jarlskog, N. Javadov, T. Javůrek, L. Jeanty, J. Jejelava, G.-Y. Jeng, D. Jennens, P. Jenni, J. Jentzsch, C. Jeske, S. Jézéquel, H. Ji, J. Jia, Y. Jiang, S. Jiggins, J. Jimenez Pena, S. Jin, A. Jinaru, O. Jinnouchi, M. D. Joergensen, P. Johansson, K. A. Johns, K. Jon-And, G. Jones, R. W. L. Jones, T. J. Jones, J. Jongmanns, P. M. Jorge, K. D. Joshi, J. Jovicevic, X. Ju, C. A. Jung, P. Jussel, A. Juste Rozas, M. Kaci, A. Kaczmarska, M. Kado, H. Kagan, M. Kagan, S. J. Kahn, E. Kajomovitz, C. W. Kalderon, S. Kama, A. Kamenshchikov, N. Kanaya, S. Kaneti, V. A. Kantserov, J. Kanzaki, B. Kaplan, L. S. Kaplan, A. Kapliy, D. Kar, K. Karakostas, A. Karamaoun, N. Karastathis, M. J. Kareem, E. Karentzos, M. Karnevskiy, S. N. Karpov, Z. M. Karpova, K. Karthik, V. Kartvelishvili, A. N. Karyukhin, L. Kashif, R. D. Kass, A. Kastanas, Y. Kataoka, C. Kato, A. Katre, J. Katzy, K. Kawagoe, T. Kawamoto, G. Kawamura, S. Kazama, V. F. Kazanin, R. Keeler, R. Kehoe, J. S. Keller, J. J. Kempster, H. Keoshkerian, O. Kepka, B. P. Kerševan, S. Kersten, R. A. Keyes, F. Khalil-zada, H. Khandanyan, A. Khanov, A. G. Kharlamov, T. J. Khoo, V. Khovanskiy, E. Khramov, J. Khubua, S. Kido, H. Y. Kim, S. H. Kim, Y. K. Kim, N. Kimura, O. M. Kind, B. T. King, M. King, S. B. King, J. Kirk, A. E. Kiryunin, T. Kishimoto, D. Kisielewska, F. Kiss, K. Kiuchi, O. Kivernyk, E. Kladiva, M. H. Klein, M. Klein, U. Klein, K. Kleinknecht, P. Klimek, A. Klimentov, R. Klingenberg, J. A. Klinger, T. Klioutchnikova, E.-E. Kluge, P. Kluit, S. Kluth, J. Knapik, E. Kneringer, E. B. F. G. Knoops, A. Knue, A. Kobayashi, D. Kobayashi, T. Kobayashi, M. Kobel, M. Kocian, P. Kodys, T. Koffas, E. Koffeman, L. A. Kogan, S. Kohlmann, Z. Kohout, T. Kohriki, T. Koi, H. Kolanoski, I. Koletsou, A. A. Komar, Y. Komori, T. Kondo, N. Kondrashova, K. Köneke, A. C. König, T. Kono, R. Konoplich, N. Konstantinidis, R. Kopeliansky, S. Koperny, L. Köpke, A. K. Kopp, K. Korcyl, K. Kordas, A. Korn, A. A. Korol, I. Korolkov, E. V. Korolkova, O. Kortner, S. Kortner, T. Kosek, V. V. Kostyukhin, V. M. Kotov, A. Kotwal, A. Kourkoumeli-Charalampidi, C. Kourkoumelis, V. Kouskoura, A. Koutsman, R. Kowalewski, T. Z. Kowalski, W. Kozanecki, A. S. Kozhin, V. A. Kramarenko, G. Kramberger, D. Krasnopevtsev, M. W. Krasny, A. Krasznahorkay, J. K. Kraus, A. Kravchenko, S. Kreiss, M. Kretz, J. Kretzschmar, K. Kreutzfeldt, P. Krieger, K. Krizka, K. Kroeninger, H. Kroha, J. Kroll, J. Kroseberg, J. Krstic, U. Kruchonak, H. Krüger, N. Krumnack, A. Kruse, M. C. Kruse, M. Kruskal, T. Kubota, H. Kucuk, S. Kuday, S. Kuehn, A. Kugel, F. Kuger, A. Kuhl, T. Kuhl, V. Kukhtin, R. Kukla, Y. Kulchitsky, S. Kuleshov, M. Kuna, T. Kunigo, A. Kupco, H. Kurashige, Y. A. Kurochkin, V. Kus, E. S. Kuwertz, M. Kuze, J. Kvita, T. Kwan, D. Kyriazopoulos, A. La Rosa, J. L. La Rosa Navarro, L. La Rotonda, C. Lacasta, F. Lacava, J. Lacey, H. Lacker, D. Lacour, V. R. Lacuesta, E. Ladygin, R. Lafaye, B. Laforge, T. Lagouri, S. Lai, L. Lambourne, S. Lammers, C. L. Lampen, W. Lampl, E. Lançon, U. Landgraf, M. P. J. Landon, V. S. Lang, J. C. Lange, A. J. Lankford, F. Lanni, K. Lantzsch, A. Lanza, S. Laplace, C. Lapoire, J. F. Laporte, T. Lari, F. Lasagni Manghi, M. Lassnig, P. Laurelli, W. Lavrijsen, A. T. Law, P. Laycock, T. Lazovich, O. Le Dortz, E. Le Guirriec, E. Le Menedeu, M. LeBlanc, T. LeCompte, F. Ledroit-Guillon, C. A. Lee, S. C. Lee, L. Lee, G. Lefebvre, M. Lefebvre, F. Legger, C. Leggett, A. Lehan, G. Lehmann Miotto, X. Lei, W. A. Leight, A. Leisos, A. G. Leister, M. A. L. Leite, R. Leitner, D. Lellouch, B. Lemmer, K. J. C. Leney, T. Lenz, B. Lenzi, R. Leone, S. Leone, C. Leonidopoulos, S. Leontsinis, C. Leroy, C. G. Lester, M. Levchenko, J. Levêque, D. Levin, L. J. Levinson, M. Levy, A. Lewis, A. M. Leyko, M. Leyton, B. Li, H. Li, H. L. Li, L. Li, S. Li, X. Li, Y. Li, Z. Liang, H. Liao, B. Liberti, A. Liblong, P. Lichard, K. Lie, J. Liebal, W. Liebig, C. Limbach, A. Limosani, S. C. Lin, T. H. Lin, F. Linde, B. E. Lindquist, J. T. Linnemann, E. Lipeles, A. Lipniacka, M. Lisovyi, T. M. Liss, D. Lissauer, A. Lister, A. M. Litke, B. Liu, D. Liu, H. Liu, J. Liu, J. B. Liu, K. Liu, L. Liu, M. Liu, Y. Liu, M. Livan, A. Lleres, J. Llorente Merino, S. L. Lloyd, F. Lo Sterzo, E. Lobodzinska, P. Loch, W. S. Lockman, F. K. Loebinger, A. E. Loevschall-Jensen, A. Loginov, T. Lohse, K. Lohwasser, M. Lokajicek, B. A. Long, J. D. Long, R. E. Long, K. A. Looper, L. Lopes, D. Lopez Mateos, B. Lopez Paredes, I. Lopez Paz, J. Lorenz, N. Lorenzo Martinez, M. Losada, P. J. Lösel, X. Lou, A. Lounis, J. Love, P. A. Love, N. Lu, H. J. Lubatti, C. Luci, A. Lucotte, F. Luehring, W. Lukas, L. Luminari, O. Lundberg, B. Lund-Jensen, D. Lynn, R. Lysak, E. Lytken, H. Ma, L. L. Ma, G. Maccarrone, A. Macchiolo, C. M. Macdonald, B. Maček, J. Machado Miguens, D. Macina, D. Madaffari, R. Madar, H. J. Maddocks, W. F. Mader, A. Madsen, J. Maeda, S. Maeland, T. Maeno, A. Maevskiy, E. Magradze, K. Mahboubi, J. Mahlstedt, C. Maiani, C. Maidantchik, A. A. Maier, T. Maier, A. Maio, S. Majewski, Y. Makida, N. Makovec, B. Malaescu, Pa. Malecki, V. P. Maleev, F. Malek, U. Mallik, D. Malon, C. Malone, S. Maltezos, V. M. Malyshev, S. Malyukov, J. Mamuzic, G. Mancini, B. Mandelli, L. Mandelli, I. Mandić, R. Mandrysch, J. Maneira, A. Manfredini, L. Manhaes de Andrade Filho, J. Manjarres Ramos, A. Mann, A. Manousakis-Katsikakis, B. Mansoulie, R. Mantifel, M. Mantoani, L. Mapelli, L. March, G. Marchiori, M. Marcisovsky, C. P. Marino, M. Marjanovic, D. E. Marley, F. Marroquim, S. P. Marsden, Z. Marshall, L. F. Marti, S. Marti-Garcia, B. Martin, T. A. Martin, V. J. Martin, B. Martin dit Latour, M. Martinez, S. Martin-Haugh, V. S. Martoiu, A. C. Martyniuk, M. Marx, F. Marzano, A. Marzin, L. Masetti, T. Mashimo, R. Mashinistov, J. Masik, A. L. Maslennikov, I. Massa, L. Massa, N. Massol, P. Mastrandrea, A. Mastroberardino, T. Masubuchi, P. Mättig, Jm. Mattmann, J. Maurer, S. J. Maxfield, D. A. Maximov, R. Mazini, S. M. Mazza, L. Mazzaferro, G. Mc Goldrick, S. P. Mc Kee, A. McCarn, R. L. McCarthy, T. G. McCarthy, N. A. McCubbin, K. W. McFarlane, J. A. Mcfayden, G. Mchedlidze, S. J. McMahon, R. A. McPherson, M. Medinnis, S. Meehan, S. Mehlhase, A. Mehta, K. Meier, C. Meineck, B. Meirose, B. R. Mellado Garcia, F. Meloni, A. Mengarelli, S. Menke, E. Meoni, K. M. Mercurio, S. Mergelmeyer, P. Mermod, L. Merola, C. Meroni, F. S. Merritt, A. Messina, J. Metcalfe, A. S. Mete, C. Meyer, J-P. Meyer, J. Meyer, H. Meyer Zu Theenhausen, R. P. Middleton, S. Miglioranzi, L. Mijović, G. Mikenberg, M. Mikestikova, M. Mikuž, M. Milesi, A. Milic, D. W. Miller, C. Mills, A. Milov, D. A. Milstead, A. A. Minaenko, Y. Minami, I. A. Minashvili, A. I. Mincer, B. Mindur, M. Mineev, Y. Ming, L. M. Mir, T. Mitani, J. Mitrevski, V. A. Mitsou, A. Miucci, P. S. Miyagawa, J. U. Mjörnmark, T. Moa, K. Mochizuki, S. Mohapatra, W. Mohr, S. Molander, R. Moles-Valls, R. Monden, K. Mönig, C. Monini, J. Monk, E. Monnier, J. Montejo Berlingen, F. Monticelli, S. Monzani, R. W. Moore, N. Morange, D. Moreno, M. Moreno Llácer, P. Morettini, D. Mori, M. Morii, M. Morinaga, V. Morisbak, S. Moritz, A. K. Morley, G. Mornacchi, J. D. Morris, S. S. Mortensen, A. Morton, L. Morvaj, M. Mosidze, J. Moss, K. Motohashi, R. Mount, E. Mountricha, S. V. Mouraviev, E. J. W. Moyse, S. Muanza, R. D. Mudd, F. Mueller, J. Mueller, R. S. P. Mueller, T. Mueller, D. Muenstermann, P. Mullen, G. A. Mullier, J. A. Murillo Quijada, W. J. Murray, H. Musheghyan, E. Musto, A. G. Myagkov, M. Myska, B. P. Nachman, O. Nackenhorst, J. Nadal, K. Nagai, R. Nagai, Y. Nagai, K. Nagano, A. Nagarkar, Y. Nagasaka, K. Nagata, M. Nagel, E. Nagy, A. M. Nairz, Y. Nakahama, K. Nakamura, T. Nakamura, I. Nakano, H. Namasivayam, R. F. Naranjo Garcia, R. Narayan, D. I. Narrias Villar, T. Naumann, G. Navarro, R. Nayyar, H. A. Neal, P. Yu. Nechaeva, T. J. Neep, P. D. Nef, A. Negri, M. Negrini, S. Nektarijevic, C. Nellist, A. Nelson, S. Nemecek, P. Nemethy, A. A. Nepomuceno, M. Nessi, M. S. Neubauer, M. Neumann, R. M. Neves, P. Nevski, P. R. Newman, D. H. Nguyen, R. B. Nickerson, R. Nicolaidou, B. Nicquevert, J. Nielsen, N. Nikiforou, A. Nikiforov, V. Nikolaenko, I. Nikolic-Audit, K. Nikolopoulos, J. K. Nilsen, P. Nilsson, Y. Ninomiya, A. Nisati, R. Nisius, T. Nobe, M. Nomachi, I. Nomidis, T. Nooney, S. Norberg, M. Nordberg, O. Novgorodova, S. Nowak, M. Nozaki, L. Nozka, K. Ntekas, G. Nunes Hanninger, T. Nunnemann, E. Nurse, F. Nuti, B. J. O’Brien, F. O’grady, D. C. O’Neil, V. O’Shea, F. G. Oakham, H. Oberlack, T. Obermann, J. Ocariz, A. Ochi, I. Ochoa, J. P. Ochoa-Ricoux, S. Oda, S. Odaka, H. Ogren, A. Oh, S. H. Oh, C. C. Ohm, H. Ohman, H. Oide, W. Okamura, H. Okawa, Y. Okumura, T. Okuyama, A. Olariu, S. A. Olivares Pino, D. Oliveira Damazio, E. Oliver Garcia, A. Olszewski, J. Olszowska, A. Onofre, K. Onogi, P. U. E. Onyisi, C. J. Oram, M. J. Oreglia, Y. Oren, D. Orestano, N. Orlando, C. Oropeza Barrera, R. S. Orr, B. Osculati, R. Ospanov, G. Otero y Garzon, H. Otono, M. Ouchrif, F. Ould-Saada, A. Ouraou, K. P. Oussoren, Q. Ouyang, A. Ovcharova, M. Owen, R. E. Owen, V. E. Ozcan, N. Ozturk, K. Pachal, A. Pacheco Pages, C. Padilla Aranda, M. Pagáčová, S. Pagan Griso, E. Paganis, F. Paige, P. Pais, K. Pajchel, G. Palacino, S. Palestini, M. Palka, D. Pallin, A. Palma, Y. B. Pan, E. Panagiotopoulou, C. E. Pandini, J. G. Panduro Vazquez, P. Pani, S. Panitkin, D. Pantea, L. Paolozzi, Th. D. Papadopoulou, K. Papageorgiou, A. Paramonov, D. Paredes Hernandez, M. A. Parker, K. A. Parker, F. Parodi, J. A. Parsons, U. Parzefall, E. Pasqualucci, S. Passaggio, F. Pastore, Fr. Pastore, G. Pásztor, S. Pataraia, N. D. Patel, J. R. Pater, T. Pauly, J. Pearce, B. Pearson, L. E. Pedersen, M. Pedersen, S. Pedraza Lopez, R. Pedro, S. V. Peleganchuk, D. Pelikan, O. Penc, C. Peng, H. Peng, B. Penning, J. Penwell, D. V. Perepelitsa, E. Perez Codina, M. T. Pérez García-Estañ, L. Perini, H. Pernegger, S. Perrella, R. Peschke, V. D. Peshekhonov, K. Peters, R. F. Y. Peters, B. A. Petersen, T. C. Petersen, E. Petit, A. Petridis, C. Petridou, P. Petroff, E. Petrolo, F. Petrucci, N. E. Pettersson, R. Pezoa, P. W. Phillips, G. Piacquadio, E. Pianori, A. Picazio, E. Piccaro, M. Piccinini, M. A. Pickering, R. Piegaia, D. T. Pignotti, J. E. Pilcher, A. D. Pilkington, J. Pina, M. Pinamonti, J. L. Pinfold, A. Pingel, S. Pires, H. Pirumov, M. Pitt, C. Pizio, L. Plazak, M.-A. Pleier, V. Pleskot, E. Plotnikova, P. Plucinski, D. Pluth, R. Poettgen, L. Poggioli, D. Pohl, G. Polesello, A. Poley, A. Policicchio, R. Polifka, A. Polini, C. S. Pollard, V. Polychronakos, K. Pommès, L. Pontecorvo, B. G. Pope, G. A. Popeneciu, D. S. Popovic, A. Poppleton, S. Pospisil, K. Potamianos, I. N. Potrap, C. J. Potter, C. T. Potter, G. Poulard, J. Poveda, V. Pozdnyakov, P. Pralavorio, A. Pranko, S. Prasad, S. Prell, D. Price, L. E. Price, M. Primavera, S. Prince, M. Proissl, K. Prokofiev, F. Prokoshin, E. Protopapadaki, S. Protopopescu, J. Proudfoot, M. Przybycien, E. Ptacek, D. Puddu, E. Pueschel, D. Puldon, M. Purohit, P. Puzo, J. Qian, G. Qin, Y. Qin, A. Quadt, D. R. Quarrie, W. B. Quayle, M. Queitsch-Maitland, D. Quilty, S. Raddum, V. Radeka, V. Radescu, S. K. Radhakrishnan, P. Radloff, P. Rados, F. Ragusa, G. Rahal, S. Rajagopalan, M. Rammensee, C. Rangel-Smith, F. Rauscher, S. Rave, T. Ravenscroft, M. Raymond, A. L. Read, N. P. Readioff, D. M. Rebuzzi, A. Redelbach, G. Redlinger, R. Reece, K. Reeves, L. Rehnisch, J. Reichert, H. Reisin, M. Relich, C. Rembser, H. Ren, A. Renaud, M. Rescigno, S. Resconi, O. L. Rezanova, P. Reznicek, R. Rezvani, R. Richter, S. Richter, E. Richter-Was, O. Ricken, M. Ridel, P. Rieck, C. J. Riegel, J. Rieger, O. Rifki, M. Rijssenbeek, A. Rimoldi, L. Rinaldi, B. Ristić, E. Ritsch, I. Riu, F. Rizatdinova, E. Rizvi, S. H. Robertson, A. Robichaud-Veronneau, D. Robinson, J. E. M. Robinson, A. Robson, C. Roda, S. Roe, O. Røhne, S. Rolli, A. Romaniouk, M. Romano, S. M. Romano Saez, E. Romero Adam, N. Rompotis, M. Ronzani, L. Roos, E. Ros, S. Rosati, K. Rosbach, P. Rose, P. L. Rosendahl, O. Rosenthal, V. Rossetti, E. Rossi, L. P. Rossi, J. H. N. Rosten, R. Rosten, M. Rotaru, I. Roth, J. Rothberg, D. Rousseau, C. R. Royon, A. Rozanov, Y. Rozen, X. Ruan, F. Rubbo, I. Rubinskiy, V. I. Rud, C. Rudolph, M. S. Rudolph, F. Rühr, A. Ruiz-Martinez, Z. Rurikova, N. A. Rusakovich, A. Ruschke, H. L. Russell, J. P. Rutherfoord, N. Ruthmann, Y. F. Ryabov, M. Rybar, G. Rybkin, N. C. Ryder, A. F. Saavedra, G. Sabato, S. Sacerdoti, A. Saddique, H. F-W. Sadrozinski, R. Sadykov, F. Safai Tehrani, M. Sahinsoy, M. Saimpert, T. Saito, H. Sakamoto, Y. Sakurai, G. Salamanna, A. Salamon, J. E. Salazar Loyola, M. Saleem, D. Salek, P. H. Sales De Bruin, D. Salihagic, A. Salnikov, J. Salt, D. Salvatore, F. Salvatore, A. Salvucci, A. Salzburger, D. Sammel, D. Sampsonidis, A. Sanchez, J. Sánchez, V. Sanchez Martinez, H. Sandaker, R. L. Sandbach, H. G. Sander, M. P. Sanders, M. Sandhoff, C. Sandoval, R. Sandstroem, D. P. C. Sankey, M. Sannino, A. Sansoni, C. Santoni, R. Santonico, H. Santos, I. Santoyo Castillo, K. Sapp, A. Sapronov, J. G. Saraiva, B. Sarrazin, O. Sasaki, Y. Sasaki, K. Sato, G. Sauvage, E. Sauvan, G. Savage, P. Savard, C. Sawyer, L. Sawyer, J. Saxon, C. Sbarra, A. Sbrizzi, T. Scanlon, D. A. Scannicchio, M. Scarcella, V. Scarfone, J. Schaarschmidt, P. Schacht, D. Schaefer, R. Schaefer, J. Schaeffer, S. Schaepe, S. Schaetzel, U. Schäfer, A. C. Schaffer, D. Schaile, R. D. Schamberger, V. Scharf, V. A. Schegelsky, D. Scheirich, M. Schernau, C. Schiavi, C. Schillo, M. Schioppa, S. Schlenker, K. Schmieden, C. Schmitt, S. Schmitt, B. Schneider, Y. J. Schnellbach, U. Schnoor, L. Schoeffel, A. Schoening, B. D. Schoenrock, E. Schopf, A. L. S. Schorlemmer, M. Schott, D. Schouten, J. Schovancova, S. Schramm, M. Schreyer, C. Schroeder, N. Schuh, M. J. Schultens, H.-C. Schultz-Coulon, H. Schulz, M. Schumacher, B. A. Schumm, Ph. Schune, C. Schwanenberger, A. Schwartzman, T. A. Schwarz, Ph. Schwegler, H. Schweiger, Ph. Schwemling, R. Schwienhorst, J. Schwindling, T. Schwindt, F. G. Sciacca, E. Scifo, G. Sciolla, F. Scuri, F. Scutti, J. Searcy, G. Sedov, E. Sedykh, P. Seema, S. C. Seidel, A. Seiden, F. Seifert, J. M. Seixas, G. Sekhniaidze, K. Sekhon, S. J. Sekula, D. M. Seliverstov, N. Semprini-Cesari, C. Serfon, L. Serin, L. Serkin, T. Serre, M. Sessa, R. Seuster, H. Severini, T. Sfiligoj, F. Sforza, A. Sfyrla, E. Shabalina, M. Shamim, L. Y. Shan, R. Shang, J. T. Shank, M. Shapiro, P. B. Shatalov, K. Shaw, S. M. Shaw, A. Shcherbakova, C. Y. Shehu, P. Sherwood, L. Shi, S. Shimizu, C. O. Shimmin, M. Shimojima, M. Shiyakova, A. Shmeleva, D. Shoaleh Saadi, M. J. Shochet, S. Shojaii, S. Shrestha, E. Shulga, M. A. Shupe, S. Shushkevich, P. Sicho, P. E. Sidebo, O. Sidiropoulou, D. Sidorov, A. Sidoti, F. Siegert, Dj. Sijacki, J. Silva, Y. Silver, S. B. Silverstein, V. Simak, O. Simard, Lj. Simic, S. Simion, E. Simioni, B. Simmons, D. Simon, P. Sinervo, N. B. Sinev, M. Sioli, G. Siragusa, A. N. Sisakyan, S. Yu. Sivoklokov, J. Sjölin, T. B. Sjursen, M. B. Skinner, H. P. Skottowe, P. Skubic, M. Slater, T. Slavicek, M. Slawinska, K. Sliwa, V. Smakhtin, B. H. Smart, L. Smestad, S. Yu. Smirnov, Y. Smirnov, L. N. Smirnova, O. Smirnova, M. N. K. Smith, R. W. Smith, M. Smizanska, K. Smolek, A. A. Snesarev, G. Snidero, S. Snyder, R. Sobie, F. Socher, A. Soffer, D. A. Soh, G. Sokhrannyi, C. A. Solans, M. Solar, J. Solc, E. Yu. Soldatov, U. Soldevila, A. A. Solodkov, A. Soloshenko, O. V. Solovyanov, V. Solovyev, P. Sommer, H. Y. Song, N. Soni, A. Sood, A. Sopczak, B. Sopko, V. Sopko, V. Sorin, D. Sosa, M. Sosebee, C. L. Sotiropoulou, R. Soualah, A. M. Soukharev, D. South, B. C. Sowden, S. Spagnolo, M. Spalla, M. Spangenberg, F. Spanò, W. R. Spearman, D. Sperlich, F. Spettel, R. Spighi, G. Spigo, L. A. Spiller, M. Spousta, T. Spreitzer, R. D. St. Denis, A. Stabile, S. Staerz, J. Stahlman, R. Stamen, S. Stamm, E. Stanecka, C. Stanescu, M. Stanescu-Bellu, M. M. Stanitzki, S. Stapnes, E. A. Starchenko, J. Stark, P. Staroba, P. Starovoitov, R. Staszewski, P. Steinberg, B. Stelzer, H. J. Stelzer, O. Stelzer-Chilton, H. Stenzel, G. A. Stewart, J. A. Stillings, M. C. Stockton, M. Stoebe, G. Stoicea, P. Stolte, S. Stonjek, A. R. Stradling, A. Straessner, M. E. Stramaglia, J. Strandberg, S. Strandberg, A. Strandlie, E. Strauss, M. Strauss, P. Strizenec, R. Ströhmer, D. M. Strom, R. Stroynowski, A. Strubig, S. A. Stucci, B. Stugu, N. A. Styles, D. Su, J. Su, R. Subramaniam, A. Succurro, Y. Sugaya, M. Suk, V. V. Sulin, S. Sultansoy, T. Sumida, S. Sun, X. Sun, J. E. Sundermann, K. Suruliz, G. Susinno, M. R. Sutton, S. Suzuki, M. Svatos, M. Swiatlowski, I. Sykora, T. Sykora, D. Ta, C. Taccini, K. Tackmann, J. Taenzer, A. Taffard, R. Tafirout, N. Taiblum, H. Takai, R. Takashima, H. Takeda, T. Takeshita, Y. Takubo, M. Talby, A. A. Talyshev, J. Y. C. Tam, K. G. Tan, J. Tanaka, R. Tanaka, S. Tanaka, B. B. Tannenwald, N. Tannoury, S. Tapprogge, S. Tarem, F. Tarrade, G. F. Tartarelli, P. Tas, M. Tasevsky, T. Tashiro, E. Tassi, A. Tavares Delgado, Y. Tayalati, F. E. Taylor, G. N. Taylor, W. Taylor, F. A. Teischinger, M. Teixeira Dias Castanheira, P. Teixeira-Dias, K. K. Temming, D. Temple, H. Ten Kate, P. K. Teng, J. J. Teoh, F. Tepel, S. Terada, K. Terashi, J. Terron, S. Terzo, M. Testa, R. J. Teuscher, T. Theveneaux-Pelzer, J. P. Thomas, J. Thomas-Wilsker, E. N. Thompson, P. D. Thompson, R. J. Thompson, A. S. Thompson, L. A. Thomsen, E. Thomson, M. Thomson, R. P. Thun, M. J. Tibbetts, R. E. Ticse Torres, V. O. Tikhomirov, Yu. A. Tikhonov, S. Timoshenko, E. Tiouchichine, P. Tipton, S. Tisserant, K. Todome, T. Todorov, S. Todorova-Nova, J. Tojo, S. Tokár, K. Tokushuku, K. Tollefson, E. Tolley, L. Tomlinson, M. Tomoto, L. Tompkins, K. Toms, E. Torrence, H. Torres, E. Torró Pastor, J. Toth, F. Touchard, D. R. Tovey, T. Trefzger, L. Tremblet, A. Tricoli, I. M. Trigger, S. Trincaz-Duvoid, M. F. Tripiana, W. Trischuk, B. Trocmé, C. Troncon, M. Trottier-McDonald, M. Trovatelli, P. True, L. Truong, M. Trzebinski, A. Trzupek, C. Tsarouchas, J. C-L. Tseng, P. V. Tsiareshka, D. Tsionou, G. Tsipolitis, N. Tsirintanis, S. Tsiskaridze, V. Tsiskaridze, E. G. Tskhadadze, I. I. Tsukerman, V. Tsulaia, S. Tsuno, D. Tsybychev, A. Tudorache, V. Tudorache, A. N. Tuna, S. A. Tupputi, S. Turchikhin, D. Turecek, R. Turra, A. J. Turvey, P. M. Tuts, A. Tykhonov, M. Tylmad, M. Tyndel, I. Ueda, R. Ueno, M. Ughetto, M. Ugland, F. Ukegawa, G. Unal, A. Undrus, G. Unel, F. C. Ungaro, Y. Unno, C. Unverdorben, J. Urban, P. Urquijo, P. Urrejola, G. Usai, A. Usanova, L. Vacavant, V. Vacek, B. Vachon, C. Valderanis, N. Valencic, S. Valentinetti, A. Valero, L. Valery, S. Valkar, E. Valladolid Gallego, S. Vallecorsa, J. A. Valls Ferrer, W. Van Den Wollenberg, P. C. Van Der Deijl, R. van der Geer, H. van der Graaf, N. van Eldik, P. van Gemmeren, J. Van Nieuwkoop, I. van Vulpen, M. C. van Woerden, M. Vanadia, W. Vandelli, R. Vanguri, A. Vaniachine, F. Vannucci, G. Vardanyan, R. Vari, E. W. Varnes, T. Varol, D. Varouchas, A. Vartapetian, K. E. Varvell, F. Vazeille, T. Vazquez Schroeder, J. Veatch, L. M. Veloce, F. Veloso, T. Velz, S. Veneziano, A. Ventura, D. Ventura, M. Venturi, N. Venturi, A. Venturini, V. Vercesi, M. Verducci, W. Verkerke, J. C. Vermeulen, A. Vest, M. C. Vetterli, O. Viazlo, I. Vichou, T. Vickey, O. E. Vickey Boeriu, G. H. A. Viehhauser, S. Viel, R. Vigne, M. Villa, M. Villaplana Perez, E. Vilucchi, M. G. Vincter, V. B. Vinogradov, I. Vivarelli, F. Vives Vaque, S. Vlachos, D. Vladoiu, M. Vlasak, M. Vogel, P. Vokac, G. Volpi, M. Volpi, H. von der Schmitt, H. von Radziewski, E. von Toerne, V. Vorobel, K. Vorobev, M. Vos, R. Voss, J. H. Vossebeld, N. Vranjes, M. Vranjes Milosavljevic, V. Vrba, M. Vreeswijk, R. Vuillermet, I. Vukotic, Z. Vykydal, P. Wagner, W. Wagner, H. Wahlberg, S. Wahrmund, J. Wakabayashi, J. Walder, R. Walker, W. Walkowiak, C. Wang, F. Wang, H. Wang, J. Wang, K. Wang, R. Wang, S. M. Wang, T. Wang, X. Wang, C. Wanotayaroj, A. Warburton, C. P. Ward, D. R. Wardrope, A. Washbrook, C. Wasicki, P. M. Watkins, A. T. Watson, I. J. Watson, M. F. Watson, G. Watts, S. Watts, B. M. Waugh, S. Webb, M. S. Weber, S. W. Weber, J. S. Webster, A. R. Weidberg, B. Weinert, J. Weingarten, C. Weiser, H. Weits, P. S. Wells, T. Wenaus, T. Wengler, S. Wenig, N. Wermes, M. Werner, P. Werner, M. Wessels, J. Wetter, K. Whalen, A. M. Wharton, A. White, M. J. White, R. White, S. White, D. Whiteson, F. J. Wickens, W. Wiedenmann, M. Wielers, P. Wienemann, C. Wiglesworth, L. A. M. Wiik-Fuchs, A. Wildauer, H. G. Wilkens, H. H. Williams, S. Williams, C. Willis, S. Willocq, A. Wilson, J. A. Wilson, I. Wingerter-Seez, F. Winklmeier, B. T. Winter, M. Wittgen, J. Wittkowski, S. J. Wollstadt, M. W. Wolter, H. Wolters, B. K. Wosiek, J. Wotschack, M. J. Woudstra, K. W. Wozniak, M. Wu, S. L. Wu, X. Wu, Y. Wu, T. R. Wyatt, B. M. Wynne, S. Xella, D. Xu, L. Xu, B. Yabsley, S. Yacoob, R. Yakabe, M. Yamada, D. Yamaguchi, Y. Yamaguchi, A. Yamamoto, S. Yamamoto, T. Yamanaka, K. Yamauchi, Y. Yamazaki, Z. Yan, H. Yang, Y. Yang, W-M. Yao, Y. Yasu, E. Yatsenko, K. H. Yau Wong, J. Ye, S. Ye, I. Yeletskikh, A. L. Yen, E. Yildirim, K. Yorita, R. Yoshida, K. Yoshihara, C. Young, C. J. S. Young, S. Youssef, D. R. Yu, J. Yu, J. M. Yu, L. Yuan, S. P. Y. Yuen, A. Yurkewicz, I. Yusuff, B. Zabinski, R. Zaidan, A. M. Zaitsev, J. Zalieckas, A. Zaman, S. Zambito, L. Zanello, D. Zanzi, C. Zeitnitz, M. Zeman, A. Zemla, Q. Zeng, K. Zengel, O. Zenin, T. Ženiš, D. Zerwas, D. Zhang, F. Zhang, H. Zhang, J. Zhang, L. Zhang, R. Zhang, X. Zhang, Z. Zhang, X. Zhao, Y. Zhao, Z. Zhao, A. Zhemchugov, J. Zhong, B. Zhou, C. Zhou, L. Zhou, M. Zhou, N. Zhou, C. G. Zhu, H. Zhu, J. Zhu, Y. Zhu, X. Zhuang, K. Zhukov, A. Zibell, D. Zieminska, N. I. Zimine, C. Zimmermann, S. Zimmermann, Z. Zinonos, M. Zinser, M. Ziolkowski, L. Živković, G. Zobernig, A. Zoccoli, M. zur Nedden, G. Zurzolo, L. Zwalinski, and ATLAS Collaboration
- Subjects
Astrophysics ,QB460-466 ,Nuclear and particle physics. Atomic energy. Radioactivity ,QC770-798 - Published
- 2022
- Full Text
- View/download PDF
29. Comparative Perspectives on Motivations and Values Among Novice Teachers
- Author
-
Margareta M. Thomson and Jean-Louis Berger
- Subjects
beliefs ,motivations ,teachers ,values ,Psychology ,BF1-990 - Abstract
The current study aims at analyzing and comparing novice teachers’ motivations, values, and beliefs (N=810) from two different countries, namely the United States and Switzerland. Both groups, the US participants (n=327) and the Swiss participants (n=483) were enrolled in a teacher training program in their respective countries. Study results identified the main teaching motivations across all subsamples as related to participants’ personal values, social values, their teaching views, and instructional beliefs. Study results show that while motivational factors were similar at many levels between the two subsamples, their teaching views and their instructional beliefs were different and varied across participants from the two countries. Findings can help educators understanding the interplay between teaching motivations and beliefs as well as cultural nuances related to these concepts.
- Published
- 2021
- Full Text
- View/download PDF
30. Urban air pollution and emergency department visits for injury in Edmonton and Toronto, Canada
- Author
-
Mieczysław Szyszkowicz, Errol M. Thomson, Nicholas de Angelis, Curtis Lavoie, and Thắng Chiến Nguyễn
- Subjects
Ambient air pollution ,Behavior ,Exposure ,Injury ,Poisoning ,Public aspects of medicine ,RA1-1270 ,Environmental sciences ,GE1-350 - Abstract
Air pollution is associated with a broad spectrum of health conditions. Among the reported associations are central nervous system effects, suggesting that air pollution may also affect human behavior and reaction time, which could in turn increase likelihood of injury. Injuries impose a significant public health and economic toll, but to our knowledge the relationship with air pollution has not been examined. This study investigated associations between air pollution and emergency department (ED) visits for injury and poisoning in two Canadian cities (Edmonton, Toronto). Daily concentrations of carbon monoxide, ozone, sulfur dioxide, nitrogen dioxide, and fine particulate matter (PM2.5), and two air quality indexes (AQHI, AQHIX; incorporating O3, NO2, and PM2.5), were considered. A time-stratified case-crossover design and conditional Poisson regression models were used to study short-term exposure effects (0 to 14 day lags). The analysis was done by sex, age group, and season. Significant positive associations were observed in both cities, albeit with some differences in the pattern of effects across strata. Relative risks (RR) and 95% confidence intervals (CI) for an interquartile range (IQR) increase of NO2 (IQR=13.0 ppb, Edmonton) in cold season (October-March) for male were RR=1.012 (95% CI: 1.005, 1.018), 1.025 (1.018, 1.031), 1.026 (1.020, 1.033), and 1.025 (1.019, 1.032), for lags from 0 to 3 days, respectively. The corresponding results in Toronto (IQR=8.8 ppb) were: 1.010 (1.004, 1.017), 1.007 (1.000, 1.013), 1.009 (1.003, 1.016), and 1.007 (1.000, 1.013). The data suggest a potential association between air pollution and increased number of ED visits for injury.
- Published
- 2022
- Full Text
- View/download PDF
31. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
- Author
-
Horacio Gil, Elena Delgado, Sonia Benito, María Moreno-Lorenzo, Michael M. Thomson, and the Spanish Group for the Study of Antiretroviral Drug Resistance
- Subjects
HIV-1 ,Spain ,integrase strand transfer inhibitors ,resistance mutation ,antirretroviral resistance ,Microbiology ,QR1-502 - Abstract
Integrase strand transfer inhibitor (INSTI)-containing regimens in HIV-1-infected patients have experienced a global increase. Recently, WHO has emphasized the need to fast-track the transition to dolutegravir (DTG)-based antiretroviral (ARV) treatments. However, continued surveillance of INSTI resistance is recommended. In this study, clinical, epidemiological, and virological features associated with INSTI resistance diagnosed in Spain were analyzed. Samples collected between 2008 and 2021 from HIV-1-infected patients were analyzed in integrase, protease, and reverse transcriptase using Sanger population sequencing. ARV drug resistance was evaluated with the Stanford University HIVdb program. Among 2,696 patients, 174 (6.5%) had INSTI resistance, all of them to first-generation INSTIs, and 71 (2.6%) had also resistance to second-generation INSTIs. Of these, only 5 individuals were exposed to DTG as the only INSTI, in whom resistance development was associated with poor treatment adherence and/or resistance to other ARV classes. Of newly HIV-1-diagnosed individuals, 0.92% harbored INSTI-resistant viruses, with low prevalences maintained along time, and only one had low-level resistance to DTG. Persons who inject drugs, age over 39 years, resistance to other ARV classes, and longer time from diagnosis were associated with INSTI resistance (p
- Published
- 2022
- Full Text
- View/download PDF
32. Characterizing and correcting immune dysfunction in non-tuberculous mycobacterial disease
- Author
-
Champa N. Ratnatunga, Katie Tungatt, Carla Proietti, Sam Halstrom, Michael R. Holt, Viviana P. Lutzky, Patricia Price, Denise L. Doolan, Scott C. Bell, Matt A. Field, Andreas Kupz, Rachel M. Thomson, and John J. Miles
- Subjects
non-tuberculous mycobacteria ,mycobacterial immunity ,immune cell dysfunction ,high-dimensional immunoprofiling ,immune modulation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic, progressive, and growing worldwide health burden associated with mounting morbidity, mortality, and economic costs. Improvements in NTM-PD management are urgently needed, which requires a better understanding of fundamental immunopathology. Here, we examine temporal dynamics of the immune compartment during NTM-PD caused by Mycobacterium avium complex (MAC) and Mycobactereoides abscessus complex (MABS). We show that active MAC infection is characterized by elevated T cell immunoglobulin and mucin-domain containing-3 expression across multiple T cell subsets. In contrast, active MABS infection was characterized by increased expression of cytotoxic T-lymphocyte-associated protein 4. Patients who failed therapy closely mirrored the healthy individual immune phenotype, with circulating immune network appearing to ‘ignore’ infection in the lung. Interestingly, immune biosignatures were identified that could inform disease stage and infecting species with high accuracy. Additionally, programmed cell death protein 1 blockade rescued antigen-specific IFN-γ secretion in all disease stages except persistent infection, suggesting the potential to redeploy checkpoint blockade inhibitors for NTM-PD. Collectively, our results provide new insight into species-specific ‘immune chatter’ occurring during NTM-PD and provide new targets, processes and pathways for diagnostics, prognostics, and treatments needed for this emerging and difficult to treat disease.
- Published
- 2022
- Full Text
- View/download PDF
33. A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes
- Author
-
Leire Pedrosa, Carles Foguet, Helena Oliveres, Iván Archilla, Marta García de Herreros, Adela Rodríguez, Antonio Postigo, Daniel Benítez-Ribas, Jordi Camps, Miriam Cuatrecasas, Antoni Castells, Aleix Prat, Timothy M. Thomson, Joan Maurel, and Marta Cascante
- Subjects
biomarker ,immunotherapy ,precision medicine ,metabolism ,immune checkpoint-based therapy ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Existing immune signatures and tumor mutational burden have only modest predictive capacity for the efficacy of immune check point inhibitors. In this study, we developed an immune-metabolic signature suitable for personalized ICI therapies. A classifier using an immune-metabolic signature (IMMETCOLS) was developed on a training set of 77 metastatic colorectal cancer (mCRC) samples and validated on 4,200 tumors from the TCGA database belonging to 11 types. Here, we reveal that the IMMETCOLS signature classifies tumors into three distinct immune-metabolic clusters. Cluster 1 displays markers of enhanced glycolisis, hexosamine byosinthesis and epithelial-to-mesenchymal transition. On multivariate analysis, cluster 1 tumors were enriched in pro-immune signature but not in immunophenoscore and were associated with the poorest median survival. Its predicted tumor metabolic features suggest an acidic-lactate-rich tumor microenvironment (TME) geared to an immunosuppressive setting, enriched in fibroblasts. Cluster 2 displays features of gluconeogenesis ability, which is needed for glucose-independent survival and preferential use of alternative carbon sources, including glutamine and lipid uptake/β-oxidation. Its metabolic features suggest a hypoxic and hypoglycemic TME, associated with poor tumor-associated antigen presentation. Finally, cluster 3 is highly glycolytic but also has a solid mitochondrial function, with concomitant upregulation of glutamine and essential amino acid transporters and the pentose phosphate pathway leading to glucose exhaustion in the TME and immunosuppression. Together, these findings suggest that the IMMETCOLS signature provides a classifier of tumors from diverse origins, yielding three clusters with distinct immune-metabolic profiles, representing a new predictive tool for patient selection for specific immune-metabolic therapeutic approaches.
- Published
- 2022
- Full Text
- View/download PDF
34. Molecular Pathways for Muscle and Adipose Tissue Are Altered between Beef Steers Classed as Choice or Standard
- Author
-
Sarah A. Haderlie, Jordan K. Hieber, Jane A. Boles, James G. Berardinelli, and Jennifer M. Thomson
- Subjects
carcass quality ,beef cattle ,adipose tissue ,muscle tissue ,transcriptomics ,Veterinary medicine ,SF600-1100 ,Zoology ,QL1-991 - Abstract
Targets for finished livestock are often determined by expected fat, either subcutaneous or intramuscular. These targets are used frequently to improve eating quality. Lower intramuscular fat, lack of product uniformity, and insufficient tenderness can negatively impact beef acceptability. This study aimed to investigate the differences in gene expression that alter metabolism and intercellular signaling in the muscle and adipose tissue in beef carcasses at different fat endpoints. In this study, longissimus thoracis muscle samples and adipose tissue were collected at harvest, and RNA was extracted and then sequenced using RNAseq. Differential expression was determined using edgeR, and p-values were adjusted using the Benjamini–Hochberg method. A corrected p-value of 0.005 and log2 (fold change) of >1 were the threshold to identify differential expression. Comparison between intermuscular and subcutaneous fat showed no differences in the genes activated in the two adipose tissue depots, suggesting that subcutaneous fat was an adequate sample. Carcass data allowed the classification of carcasses by USDA quality grades (marbling targets). In comparing muscle from Standard and Choice carcasses, 15 genes were downregulated, and 20 were upregulated. There were 49 downregulated and 113 upregulated genes comparing adipose tissue from Standard and Choice carcasses. These genes are related to the metabolism of fat and energy. This indicates that muscle transcript expression varies less than adipose. In addition, subcutaneous fat can be used to evaluate transcript changes in fat. However, it is unclear whether these fat tissues can be used as surrogates for marbling.
- Published
- 2023
- Full Text
- View/download PDF
35. Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America
- Author
-
Elena Delgado, Aurora Fernández-García, Marcos Pérez-Losada, María Moreno-Lorenzo, Ismael Fernández-Miranda, Sonia Benito, Vanessa Montero, Horacio Gil, Silvia Hernáez, Josefa Muñoz, Miren Z. Zubero-Sulibarria, Elena García-Bodas, Mónica Sánchez, Jorge del Romero, Carmen Rodríguez, Luis Elorduy, Elena Bereciartua, Esther Culebras, Icíar Rodríguez-Avial, María Luisa Giménez-Alarcón, Carmen Martín-Salas, Carmen Gómez-González, José J. García-Irure, Gema Cenzual, Ana Martínez-Sapiña, María Maiques-Camarero, Lucía Pérez-Álvarez, and Michael M. Thomson
- Subjects
Medicine ,Science - Abstract
Abstract Circulating recombinant forms (CRFs) contribute substantially to the HIV-1 pandemic. Among 105 CRFs described in the literature, 16 are BF intersubtype recombinants, most of South American origin, of which CRF12_BF is the most widely spread. A BF recombinant cluster identified in Bolivia was suggested to represent a new CRF_BF. Here we find that it belongs to a larger cluster incorporating 39 viruses collected in 7 countries from 3 continents, 22 of them in Spain, most from Bolivian or Peruvian individuals, and 12 in South America (Bolivia, Argentina, and Peru). This BF cluster comprises three major subclusters, two associated with Bolivian and one with Peruvian individuals. Near full-length genome sequence analyses of nine viruses, collected in Spain, Bolivia, and Peru, revealed coincident BF mosaic structures, with 13 breakpoints, 6 and 7 of which coincided with CRF12_BF and CRF17_BF, respectively. In a phylogenetic tree, they grouped in a clade closely related to these CRFs, and more distantly to CRF38_BF and CRF44_BF, all circulating in South America. These results allowed to identify a new HIV-1 CRF, designated CRF89_BF. Through phylodynamic analyses, CRF89_BF emergence was estimated in Bolivia around 1986. CRF89_BF is the fifth CRF member of the HIV-1 recombinant family related to CRF12_BF.
- Published
- 2021
- Full Text
- View/download PDF
36. Editorial: HIV-1 genetic diversity, volume II
- Author
-
Kok Keng Tee, Michael M. Thomson, and Joris Hemelaar
- Subjects
HIV ,subtype ,circulating recombinant form (CRF) ,unique recombinant form (URF) ,phylogenetic analysis ,recombinant ,Microbiology ,QR1-502 - Published
- 2022
- Full Text
- View/download PDF
37. Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 Mpro Main Protease Inhibitors
- Author
-
Maria Nuria Peralta-Moreno, Vanessa Anton-Muñoz, David Ortega-Alarcon, Ana Jimenez-Alesanco, Sonia Vega, Olga Abian, Adrian Velazquez-Campoy, Timothy M. Thomson, José Manuel Granadino-Roldán, Claudia Machicado, and Jaime Rubio-Martinez
- Subjects
SARS-CoV-2 main protease ,Peruvian natural plants ,docking ,molecular dynamics ,MM-PB/GBSA approach ,drug design ,Medicine ,Pharmacy and materia medica ,RS1-441 - Abstract
Over 750 million cases of COVID-19, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), have been reported since the onset of the global outbreak. The need for effective treatments has spurred intensive research for therapeutic agents based on pharmaceutical repositioning or natural products. In light of prior studies asserting the bioactivity of natural compounds of the autochthonous Peruvian flora, the present study focuses on the identification SARS-CoV-2 Mpro main protease dimer inhibitors. To this end, a target-based virtual screening was performed over a representative set of Peruvian flora-derived natural compounds. The best poses obtained from the ensemble molecular docking process were selected. These structures were subjected to extensive molecular dynamics steps for the computation of binding free energies along the trajectory and evaluation of the stability of the complexes. The compounds exhibiting the best free energy behaviors were selected for in vitro testing, confirming the inhibitory activity of Hyperoside against Mpro, with a Ki value lower than 20 µM, presumably through allosteric modulation.
- Published
- 2023
- Full Text
- View/download PDF
38. CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes
- Author
-
Dave J. Baker, Alp Aydin, Thanh Le-Viet, Gemma L. Kay, Steven Rudder, Leonardo de Oliveira Martins, Ana P. Tedim, Anastasia Kolyva, Maria Diaz, Nabil-Fareed Alikhan, Lizzie Meadows, Andrew Bell, Ana Victoria Gutierrez, Alexander J. Trotter, Nicholas M. Thomson, Rachel Gilroy, Luke Griffith, Evelien M. Adriaenssens, Rachael Stanley, Ian G. Charles, Ngozi Elumogo, John Wain, Reenesh Prakash, Emma Meader, Alison E. Mather, Mark A. Webber, Samir Dervisevic, Andrew J. Page, and Justin O’Grady
- Subjects
SARS-CoV-2 ,Nanopore ,Sequencing ,NGS ,Genome ,Genetic ,Medicine ,Genetics ,QH426-470 - Abstract
Abstract We present CoronaHiT, a platform and throughput flexible method for sequencing SARS-CoV-2 genomes (≤ 96 on MinION or > 96 on Illumina NextSeq) depending on changing requirements experienced during the pandemic. CoronaHiT uses transposase-based library preparation of ARTIC PCR products. Method performance was demonstrated by sequencing 2 plates containing 95 and 59 SARS-CoV-2 genomes on nanopore and Illumina platforms and comparing to the ARTIC LoCost nanopore method. Of the 154 samples sequenced using all 3 methods, ≥ 90% genome coverage was obtained for 64.3% using ARTIC LoCost, 71.4% using CoronaHiT-ONT and 76.6% using CoronaHiT-Illumina, with almost identical clustering on a maximum likelihood tree. This protocol will aid the rapid expansion of SARS-CoV-2 genome sequencing globally.
- Published
- 2021
- Full Text
- View/download PDF
39. Evaluating wildlife translocations using genomics: A bighorn sheep case study
- Author
-
Elizabeth P. Flesch, Tabitha A. Graves, Jennifer M. Thomson, Kelly M. Proffitt, P. J. White, Thomas R. Stephenson, and Robert A. Garrott
- Subjects
bighorn sheep ,genomics ,kinship ,Ovis canadensis ,population genetics ,translocation ,Ecology ,QH540-549.5 - Abstract
Abstract Wildlife restoration often involves translocation efforts to reintroduce species and supplement small, fragmented populations. We examined the genomic consequences of bighorn sheep (Ovis canadensis) translocations and population isolation to enhance understanding of evolutionary processes that affect population genetics and inform future restoration strategies. We conducted a population genomic analysis of 511 bighorn sheep from 17 areas, including native and reintroduced populations that received 0–10 translocations. Using the Illumina High Density Ovine array, we generated datasets of 6,155 to 33,289 single nucleotide polymorphisms and completed clustering, population tree, and kinship analyses. Our analyses determined that natural gene flow did not occur between most populations, including two pairs of native herds that had past connectivity. We synthesized genomic evidence across analyses to evaluate 24 different translocation events and detected eight successful reintroductions (i.e., lack of signal for recolonization from nearby populations) and five successful augmentations (i.e., reproductive success of translocated individuals) based on genetic similarity with the source populations. A single native population founded six of the reintroduced herds, suggesting that environmental conditions did not need to match for populations to persist following reintroduction. Augmentations consisting of 18–57 animals including males and females succeeded, whereas augmentations of two males did not result in a detectable genetic signature. Our results provide insight on genomic distinctiveness of native and reintroduced herds, information on the relative success of reintroduction and augmentation efforts and their associated attributes, and guidance to enhance genetic contribution of augmentations and reintroductions to aid in bighorn sheep restoration.
- Published
- 2020
- Full Text
- View/download PDF
40. Viruses Previously Identified in Brazil as Belonging to HIV-1 CRF72_BF1 Represent Two Closely Related Circulating Recombinant Forms, One of Which, Designated CRF122_BF1, Is Also Circulating in Spain
- Author
-
Javier E. Cañada-García, Elena Delgado, Horacio Gil, Sonia Benito, Mónica Sánchez, Antonio Ocampo, Jorge Julio Cabrera, Celia Miralles, Elena García-Bodas, Ana Mariño, Patricia Ordóñez, María José Gude, Carmen Ezpeleta, and Michael M. Thomson
- Subjects
HIV-1 ,circulating recombinant forms ,molecular epidemiology ,phylogeny ,phylodynamics ,Microbiology ,QR1-502 - Abstract
Circulating recombinant forms (CRFs) are important components of the HIV-1 pandemic. Those derived from recombination between subtype B and subsubtype F1, with 18 reported, most of them of South American origin, are among the most diverse. In this study, we identified a HIV-1 BF1 recombinant cluster that is expanding in Spain, transmitted mainly via heterosexual contact, which, analyzed in near full-length genomes in four viruses, exhibited a coincident BF1 mosaic structure, with 12 breakpoints, that fully coincided with that of two viruses (10BR_MG003 and 10BR_MG005) from Brazil, previously classified as CRF72_BF1. The three remaining Brazilian viruses (10BR_MG002, 10BR_MG004, and 10BR_MG008) previously identified as CRF72_BF1 exhibited mosaic structures highly similar, but not identical, to that of the Spanish viruses and to 10BR_MG003 and 10BR_MG005, with discrepant subtypes in two short genome segments, located in pol and gp120env. Based on these results, we propose that the five viruses from Brazil previously identified as CRF72_BF1 actually belong to two closely related CRFs, one comprising 10BR_MG002, 10BR_MG004, and 10BR_MG008, which keep their CRF72_BF1 designation, and the other, designated CRF122_BF1, comprising 10BR_MG003, 10BR_MG005, and the viruses of the identified Spanish cluster. Three other BF1 recombinant genomes, two from Brazil and one from Italy, previously identified as unique recombinant forms, were classified as CRF72_BF1. CRF122_BF1, but not CRF72_BF1, was associated with protease L89M substitution, which was reported to contribute to antiretroviral drug resistance. Phylodynamic analyses estimate the emergence of CRF122_BF1 in Brazil around 1987. Given their close phylogenetic relationship and similar structures, the grouping of CRF72_BF1 and CRF122_BF1 in a CRF family is proposed.
- Published
- 2022
- Full Text
- View/download PDF
41. The Origin, Epidemiology, and Phylodynamics of Human Immunodeficiency Virus Type 1 CRF47_BF
- Author
-
Gracelyn Hill, Marcos Pérez-Losada, Elena Delgado, Sonia Benito, Vanessa Montero, Horacio Gil, Mónica Sánchez, Javier E. Cañada-García, Elena García-Bodas, Keith A. Crandall, Michael M. Thomson, the Spanish Group for the Study of New HIV Diagnoses, José Luis Díaz de Tuesta del Arco, Silvia Hernáez, Sofía Ibarra-Ugarte, Josefa Muñoz, María Carmen Nieto-Toboso, Miren Zuriñe Zubero-Sulibarria, Elena Bereciartua-Bastarrica, Luis Elorduy, Goikoetxea-Agirre Ane Josune, Leyre López-Soria, María José López de Goikoetxea, Maitane Aranzamendi, Gustavo Cilla, José Antonio Iribarren, Yolanda Salicio, Carmen Gómez, José Joaquín Portu, Aitziber Aguinaga, Carmen Ezpeleta, Carmen Martín-Salas, María Gracia Ruiz-Alda, José Javier García-Irure, Fernando Buñuel, Francisco Jover-Díaz, Jorge Julio Cabrera, Antonio Ocampo, Celia Miralles, Julio Diz-Aren, Matilde Trigo, María José Gude, Ramón Rabuñal, Eva María Romay, Ricardo Fernández-Rodríguez, Juan García-Costa, Ana María Martínez-Sapiña, Jorge del Romero, Belén Lorenzo-Vidal, and César Gómez
- Subjects
HIV ,phylodynamics ,circulating recombinant form (CRF) ,Spain ,epidemiology ,CRF47_BF ,Microbiology ,QR1-502 - Abstract
CRF47_BF is a circulating recombinant form (CRF) of the human immunodeficiency virus type 1 (HIV-1), the etiological agent of AIDS. CRF47_BF represents one of 19 CRFx_BFs and has a geographic focus in Spain, where it was first identified in 2010. Since its discovery, CRF47_BF has expanded considerably in Spain, predominantly through heterosexual contact (∼56% of the infections). Little is known, however, about the origin and diversity of this CRF or its epidemiological correlates, as very few samples have been available so far. This study conducts a phylogenetic analysis with representatives of all CRFx_BF sequence types along with HIV-1 M Group subtypes to validate that the CRF47_BF sequences share a unique evolutionary history. The CRFx_BF sequences cluster into a single, not well supported, clade that includes their dominant parent subtypes (B and F). This clade also includes subtype D and excludes sub-subtype F2. However, the CRF47_BF sequences all share a most recent common ancestor. Further analysis of this clade couples CRF47_BF protease-reverse transcriptase sequences and epidemiological data from an additional 87 samples collected throughout Spain, as well as additional CRF47_BF database sequences from Brazil and Spain to investigate the origin and phylodynamics of CRF47_BF. The Spanish region with the highest proportion of CRF47_BF samples in the data set was the Basque Country (43.7%) with Navarre next highest at 19.5%. We include in our analysis epidemiological data on host sex, mode of transmission, time of collection, and geographic region. The phylodynamic analysis indicates that CRF47_BF originated in Brazil around 1999–2000 and spread to Spain from Brazil in 2002–2003. The virus spread rapidly throughout Spain with an increase in population size from 2011 to 2015 and leveling off more recently. Three strongly supported clusters associated with Spanish regions (Basque Country, Navarre, and Aragon), together comprising 60.8% of the Spanish samples, were identified, one of which was also associated with transmission among men who have sex with men. The expansion in Spain of CRF47_BF, together with that of other CRFs and subtype variants of South American origin, previously reported, reflects the increasing relationship between the South American and European HIV-1 epidemics.
- Published
- 2022
- Full Text
- View/download PDF
42. Remarkable genomic diversity among Escherichia isolates recovered from healthy chickens
- Author
-
Nicholas M. Thomson, Rachel Gilroy, Maria Getino, Ebenezer Foster-Nyarko, Arnoud H.M. van Vliet, Roberto M. La Ragione, and Mark J. Pallen
- Subjects
Escherichia ,Genomic diversity ,Chickens ,Phylogenomics ,Commensal ,Cryptic clades ,Medicine ,Biology (General) ,QH301-705.5 - Abstract
The genus Escherichia has been extensively studied and it is known to encompass a range of commensal and pathogenic bacteria that primarily inhabit the gastrointestinal tracts of warm-blooded vertebrates. However, the presence of E. coli as a model organism and potential pathogen has diverted attention away from commensal strains and other species in the genus. To investigate the diversity of Escherichia in healthy chickens, we collected fecal samples from antibiotic-free Lohmann Brown layer hens and determined the genome sequences of 100 isolates, 81 of which were indistinguishable at the HC0 level of the Hierarchical Clustering of Core Genome Multi-Locus Sequence Typing scheme. Despite initial selection on CHROMagar Orientation medium, which is considered selective for E. coli, in silico phylotyping and core genome single nucleotide polymorphism analysis revealed the presence of at least one representative of all major clades of Escherichia, except for E. albertii, Shigella, and E. coli phylogroup B2 and cryptic clade I. The most frequent phylogenomic groups were E. coli phylogroups A and B1 and E. ruysiae (clades III and IV). We compiled a collection of reference strains isolated from avian sources (predominantly chicken), representing every Escherichia phylogroup and species, and used it to confirm the phylogeny and diversity of our isolates. Overall, the isolates carried low numbers of the virulence and antibiotic resistance genes typically seen in avian pathogenic E. coli. Notably, the clades not recovered are ones that have been most strongly associated with virulence by other studies.
- Published
- 2022
- Full Text
- View/download PDF
43. Transmission Clusters, Predominantly Associated With Men Who Have Sex With Men, Play a Main Role in the Propagation of HIV-1 in Northern Spain (2013–2018)
- Author
-
Horacio Gil, Elena Delgado, Sonia Benito, Leonidas Georgalis, Vanessa Montero, Mónica Sánchez, Javier E. Cañada-García, Elena García-Bodas, Asunción Díaz, Michael M. Thomson, and The Members of the Spanish Group for the Study of New HIV Diagnoses
- Subjects
Spain ,HIV-1 ,transmission clusters ,molecular epidemiology ,men who have sex with men ,migrants ,Microbiology ,QR1-502 - Abstract
Viruses of HIV-1-infected individuals whose transmission is related group phylogenetically in transmission clusters (TCs). The study of the phylogenetic relations of these viruses and the factors associated with these individuals is essential to analyze the HIV-1 epidemic. In this study, we examine the role of TCs in the epidemiology of HIV-1 infection in Galicia and the Basque County, two regions of northern Spain. A total of 1,158 HIV-1-infected patients from both regions with new diagnoses (NDs) in 2013–2018 were included in the study. Partial HIV-1 pol sequences were analyzed phylogenetically by approximately maximum-likelihood with FastTree 2. In this analysis, 10,687 additional sequences from samples from HIV-1-infected individuals collected in Spain in 1999–2019 were also included to assign TC membership and to determine TCs’ sizes. TCs were defined as those which included viruses from ≥4 individuals, at least 50% of them Spaniards, and with ≥0.95 Shimodaira-Hasegawa-like node support in the phylogenetic tree. Factors associated to TCs were evaluated using odds ratios (OR) and their 95% CI. Fifty-one percent of NDs grouped in 162 TCs. Male patients (OR: 2.6; 95% CI: 1.5–4.7) and men having sex with men (MSM; OR: 2.1; 95% CI: 1.4–3.2) had higher odds of belonging to a TC compared to female and heterosexual patients, respectively. Individuals from Latin America (OR: 0.3; 95% CI: 0.2–0.4), North Africa (OR: 0.4; 95% CI: 0.2–1.0), and especially Sub-Saharan Africa (OR: 0.02; 95% CI: 0.003–0.2) were inversely associated to belonging to TCs compared to native Spaniards. Our results show that TCs are important components of the HIV-1 epidemics in the two Spanish regions studied, where transmission between MSM is predominant. The majority of migrants were infected with viruses not belonging to TCs that expand in Spain. Molecular epidemiology is essential to identify local peculiarities of HIV-1 propagation. The early detection of TCs and prevention of their expansion, implementing effective control measures, could reduce HIV-1 infections.
- Published
- 2022
- Full Text
- View/download PDF
44. Restoration of wild-type motility to flagellin-knockout Escherichia coli by varying promoter, copy number and induction strength in plasmid-based expression of flagellin
- Author
-
Nicholas M. Thomson and Mark J. Pallen
- Subjects
Flagella ,Motility ,Promoter ,Tuneable ,Plasmid ,Copy number ,Biotechnology ,TP248.13-248.65 - Abstract
Flagellin is the major constituent of the flagellar filament and faithful restoration of wild-type motility to flagellin mutants may be beneficial for studies of flagellar biology and biotechnological exploitation of the flagellar system. However, gene complementation studies often fail to report whether true wild-type motility was restored by expressing flagellin from a plasmid. Therefore, we explored the restoration of motility by flagellin expressed from a variety of combinations of promoter, plasmid copy number and induction strength. Motility was only partially (~50%) restored using the tightly regulated rhamnose promoter due to weak flagellin gene expression, but wild-type motility was regained with the T5 promoter, which, although leaky, allowed titration of induction strength. The endogenous E. coli flagellin promoter also restored wild-type motility. However, flagellin gene transcription levels increased 3.1–27.9-fold when wild-type motility was restored, indicating disturbances in the flagellar regulatory mechanisms. Motility was little affected by plasmid copy number when dependent on inducible promoters. However, plasmid copy number was important when expression was controlled by the native E. coli flagellin promoter. Motility was poorly correlated with flagellin transcription levels, but strongly correlated with the amount of flagellin associated with the flagellar filament, suggesting that excess monomers are either not exported or not assembled into filaments. This study provides a useful reference for further studies of flagellar function and a simple blueprint for similar studies with other proteins.
- Published
- 2020
- Full Text
- View/download PDF
45. Creation of Golden Gate constructs for gene doctoring
- Author
-
Nicholas M. Thomson, Chuanzhen Zhang, Eleftheria Trampari, and Mark J. Pallen
- Subjects
Gene doctoring ,Recombineering ,Golden Gate assembly ,Mutagenesis ,Enterobacteria ,Chromosome ,Biotechnology ,TP248.13-248.65 - Abstract
Abstract Background Gene doctoring is an efficient recombination-based genetic engineering approach to mutagenesis of the bacterial chromosome that combines the λ-Red recombination system with a suicide donor plasmid that is cleaved in vivo to generate linear DNA fragments suitable for recombination. The use of a suicide donor plasmid makes Gene Doctoring more efficient than other recombineering technologies. However, generation of donor plasmids typically requires multiple cloning and screening steps. Results We constructed a simplified acceptor plasmid, called pDOC-GG, for the assembly of multiple DNA fragments precisely and simultaneously to form a donor plasmid using Golden Gate assembly. Successful constructs can easily be identified through blue-white screening. We demonstrated proof of principle by inserting a gene for green fluorescent protein into the chromosome of Escherichia coli. We also provided related genetic parts to assist in the construction of mutagenesis cassettes with a tetracycline-selectable marker. Conclusions Our plasmid greatly simplifies the construction of Gene Doctoring donor plasmids and allows for the assembly of complex, multi-part insertion or deletion cassettes with a free choice of target sites and selection markers. The tools we developed are applicable to gene editing for a wide variety of purposes in Enterobacteriaceae and potentially in other diverse bacterial families.
- Published
- 2020
- Full Text
- View/download PDF
46. WHO malaria nucleic acid amplification test external quality assessment scheme: results of distribution programmes one to three
- Author
-
Jane A. Cunningham, Rebecca M. Thomson, Sean C. Murphy, Maria de la Paz Ade, Xavier C. Ding, Sandra Incardona, Eric Legrand, Naomi W. Lucchi, Didier Menard, Samuel L. Nsobya, Agatha C. Saez, Peter L. Chiodini, and Jaya Shrivastava
- Subjects
External quality assessment ,Malaria ,Molecular ,Proficiency testing ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The World Health Organization (WHO) recommends parasite-based diagnosis of malaria. In recent years, there has been surge in the use of various kinds of nucleic-acid amplification based tests (NAATs) for detection and identification of Plasmodium spp. to support clinical care in high-resource settings and clinical and epidemiological research worldwide. However, these tests are not without challenges, including lack (or limited use) of standards and lack of reproducibility, due in part to variation in protocols amongst laboratories. Therefore, there is a need for rigorous quality control, including a robust external quality assessment (EQA) scheme targeted towards malaria NAATs. To this effect, the WHO Global Malaria Programme worked with the UK National External Quality Assessment Scheme (UK NEQAS) Parasitology and with technical experts to launch a global NAAT EQA scheme in January 2017. Methods Panels of NAAT EQA specimens containing five major species of human-infecting Plasmodium at various parasite concentrations and negative samples were created in lyophilized blood (LB) and dried blood spot (DBS) formats. Two distributions per year were sent, containing five LB and five DBS specimens. Samples were tested and validated by six expert referee laboratories prior to distribution. Between 37 and 45 laboratories participated in each distribution and submitted results using the online submission portal of UK NEQAS. Participants were scored based on their laboratory’s stated capacity to identify Plasmodium species, and individual laboratory reports were sent which included performance comparison with anonymized peers. Results Analysis of the first three distributions revealed that the factors that most significantly affected performance were sample format (DBS vs LB), species and parasite density, while laboratory location and the reported methodology used (type of nucleic acid extraction, amplification, or DNA vs RNA target) did not significantly affect performance. Referee laboratories performed better than non-referee laboratories. Conclusions Globally, malaria NAAT assays now inform a range of clinical, epidemiological and research investigations. EQA schemes offer a way for laboratories to assess and improve their performance, which is critical to safeguarding the reliability of data and diagnoses especially in situations where various NAAT methodologies and protocols are in use.
- Published
- 2020
- Full Text
- View/download PDF
47. Sestrin prevents atrophy of disused and aging muscles by integrating anabolic and catabolic signals
- Author
-
Jessica Segalés, Eusebio Perdiguero, Antonio L. Serrano, Pedro Sousa-Victor, Laura Ortet, Mercè Jardí, Andrei V. Budanov, Laura Garcia-Prat, Marco Sandri, David M. Thomson, Michael Karin, Jun Hee Lee, and Pura Muñoz-Cánoves
- Subjects
Science - Abstract
Ageing is associated with muscle atrophy, which negatively impacts quality of life. Here the authors show that expression of sestrins decreases during inactivity and that their overexpression prevents atrophy in mice via modulation of autophagy and protein degradation.
- Published
- 2020
- Full Text
- View/download PDF
48. RMTable2023 and PolSpectra2023: Standards for Reporting Polarization and Faraday Rotation Measurements of Radio Sources
- Author
-
C. L. Van Eck, B. M. Gaensler, S. Hutschenreuter, J. Livingston, Y. K. Ma, C. J. Riseley, A. J. M. Thomson, B. Adebahr, A. Basu, M. Birkinshaw, T. A. Enßlin, G. Heald, S. A. Mao, and N. M. McClure-Griffiths
- Subjects
Radio astronomy ,Spectropolarimetry ,Astrophysics ,QB460-466 - Abstract
Faraday rotation measures (RMs) have been used for many studies of cosmic magnetism, and in most cases having more RMs is beneficial for those studies. This has lead to the development of RM surveys that have produced large catalogs, as well as meta-catalogs collecting RMs from many different publications. However, it has been difficult to take full advantage of all of these RMs, as the individual catalogs have been published in many different places, and in many different formats. In addition, the polarization spectra used to determine these RMs are rarely published, limiting the ability to reanalyze data as new methods or additional observations become available. We propose a standard convention for RM catalogs, RMTable2023, and a standard for source-integrated polarized spectra of radio sources, PolSpectra2023. These standards are intended to maximize the value and utility of these data for researchers and to make them easier to access. To demonstrate the use of the RMTable2023 standard, we have produced a consolidated catalog of 55,819 RMs collected from 42 published catalogs.
- Published
- 2023
- Full Text
- View/download PDF
49. Identification of CRF66_BF, a New HIV-1 Circulating Recombinant Form of South American Origin
- Author
-
Joan Bacqué, Elena Delgado, Sonia Benito, María Moreno-Lorenzo, Vanessa Montero, Horacio Gil, Mónica Sánchez, María Carmen Nieto-Toboso, Josefa Muñoz, Miren Z. Zubero-Sulibarria, Estíbaliz Ugalde, Elena García-Bodas, Javier E. Cañada, Jorge del Romero, Carmen Rodríguez, Iciar Rodríguez-Avial, Luis Elorduy-Otazua, José J. Portu, Juan García-Costa, Antonio Ocampo, Jorge J. Cabrera, and Michael M. Thomson
- Subjects
HIV-1 ,circulating recombinant form ,molecular epidemiology ,phylogeny ,phylodynamics ,Microbiology ,QR1-502 - Abstract
Circulating recombinant forms (CRFs) are important components of the HIV-1 pandemic. Among 110 reported in the literature, 17 are BF1 intersubtype recombinant, most of which are of South American origin. Among these, all 5 identified in the Southern Cone and neighboring countries, except Brazil, derive from a common recombinant ancestor related to CRF12_BF, which circulates widely in Argentina, as deduced from coincident breakpoints and clustering in phylogenetic trees. In a HIV-1 molecular epidemiological study in Spain, we identified a phylogenetic cluster of 20 samples from 3 separate regions which were of F1 subsubtype, related to the Brazilian strain, in protease-reverse transcriptase (Pr-RT) and of subtype B in integrase. Remarkably, 14 individuals from this cluster (designated BF9) were Paraguayans and only 4 were native Spaniards. HIV-1 transmission was predominantly heterosexual, except for a subcluster of 6 individuals, 5 of which were men who have sex with men. Ten additional database sequences, from Argentina (n = 4), Spain (n = 3), Paraguay (n = 1), Brazil (n = 1), and Italy (n = 1), branched within the BF9 cluster. To determine whether it represents a new CRF, near full-length genome (NFLG) sequences were obtained for 6 viruses from 3 Spanish regions. Bootscan analyses showed a coincident BF1 recombinant structure, with 5 breakpoints, located in p17gag, integrase, gp120, gp41-rev overlap, and nef, which was identical to that of two BF1 recombinant viruses from Paraguay previously sequenced in NFLGs. Interestingly, none of the breakpoints coincided with those of CRF12_BF. In a maximum likelihood phylogenetic tree, all 8 NFLG sequences grouped in a strongly supported clade segregating from previously identified CRFs and from the CRF12_BF “family” clade. These results allow us to identify a new HIV-1 CRF, designated CRF66_BF. Through a Bayesian coalescent analysis, the most recent common ancestor of CRF66_BF was estimated around 1984 in South America, either in Paraguay or Argentina. Among Pr-RT sequences obtained by us from HIV-1-infected Paraguayans living in Spain, 14 (20.9%) of 67 were of CRF66_BF, suggesting that CRF66_BF may be one of the major HIV-1 genetic forms circulating in Paraguay. CRF66_BF is the first reported non-Brazilian South American HIV-1 CRF_BF unrelated to CRF12_BF.
- Published
- 2021
- Full Text
- View/download PDF
50. Nontraditional Prospective Teachers: Motivations, Goals and Mathematical Knowledge Differences among Identified Typologies
- Author
-
Margareta M. Thomson and Valerie N. Faulkner
- Subjects
teacher education ,motivational beliefs ,motivation ,Special aspects of education ,LC8-6691 - Abstract
This mixed-methods study employed a typological approach and an Expectancy-Value framework to understand nontraditional prospective teachers’ motivational beliefs, teaching motivations, and goals for choosing a teaching career. All participants (N=88) were nontraditional prospective teachers, graduate students enrolled in a Master of Arts in Teaching (MAT) program in the United States. Data were collected in three phases, including quantitative (survey, pre-and posttest assessments), and qualitative (interviews). Analyses revealed three distinct typologies of teachers based on their motivational beliefs, and further differences among the identified groups based on other variables. The qualitative data showed general themes across participants about their teaching efficacy, motivation for teaching and quality of teacher preparation. Implications for teacher education programs are discussed.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.